Compositions and methods for treating transthyretin amyloidosis
Knocking out the TTR gene through the CRISPR/Cas system solves the problem of insufficient existing ATTR treatment methods, and achieves durable treatment for transthyroxine amyloidosis, significantly reduces TTR serum concentration and amyloid deposition, and improves the symptoms of related diseases. .
Patent Information
- Application Number
- CN202380031408.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-29
- Filing Date
- 2023-03-24
- Publication Date
- 2024-11-15
AI Technical Summary
Existing treatments for transthyroid protein amyloidosis (ATTR) are limited, especially inadequate methods to prevent disease progression and improve quality of life. Traditional small molecule stabilizers and liver transplants have safety and cost problems and cannot reverse TTR deposition. damage caused.
Compositions that knock out TTR gene expression using CRISPR/Cas system are used to identify and cleave mutant or wild-type TTR genes through guide RNA with high editing efficiency, significantly reducing or abrogating the production of TTR proteins, using RNA-guided DNA binding agents such as Cas9 Nucleases are gene edited.
Achieving durable treatment of ATTR significantly reduces TTR serum concentrations, reduces or prevents the deposition of amyloid or amyloid fibrils, improves neuro and cardiomyopathy symptoms, and provides a response to familial amyloid polyneuropathy and cardiomyopathy. Effective treatment plan.
Smart Images

Figure CN118974256A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to PCT / CN2022 / 083666 filed on March 29, 2022. The invention name of PCT / CN2022 / 083666 is “COMPOSITIONS AND METHODS FOR TREATMENT OF TRANSTHYRETINAMYLOIDOSIS”, the contents of which are incorporated herein by reference.
[0003] Sequence Listing
[0004] This application contains a sequence listing submitted electronically as an XML file, with the file name 53333-0002WO1_SL_ST26.xml. This XML file was created on March 23, 2023 and is 432,886 bytes in size. The entire contents of the material in the XML file are incorporated herein by reference. Technical Field
[0005] The present application relates to compositions and methods for treating amyloidosis associated with transthyretin (ATTR). Background Art
[0006] Transthyretin (TTR) is a transport protein that carries thyroxine and retinol in plasma. TTR is a homotetrameric protein consisting of four monomers, each of 127 amino acids. It is synthesized primarily in the liver, with smaller amounts in the choroid plexus and retina. Transthyretin amyloidosis (ATTR) is caused by the accumulation of TTR amyloid fibrils deposited extracellularly in various tissues, such as the heart and kidney. ATTR is a systemic disease manifested by polyneuropathy, autonomic neuropathy, and cardiomyopathy. Hereditary (familial) ATTR amyloidosis is caused by more than 100 autosomal dominant mutations in the TTR gene, which result in the accumulation of misfolded monomers that destabilize and dissociate the TTR tetramer. Wild-type ATTR amyloidosis has also been shown to be caused by misfolding and deposition of wild-type TTR in elderly men and is associated with heart rhythm problems, heart failure, and carpal tunnel syndrome.
[0007] There are limited treatments for ATTR amyloidosis that stop disease progression and improve quality of life (HATTR Guidelines, May 2018 Akcea Therapeutics, TTR-095-2 05 / 18). Although liver transplantation has been studied for the treatment of ATTR, its use is decreasing because liver transplantation involves significant risks and sometimes the disease continues to progress after transplantation. Small molecule stabilizers, such as diflunisal and clofazodone, appear to slow ATTR progression, but these drugs cannot stop disease progression. Diflunisal and liver transplantation cannot reverse the damage caused by TTR deposition, and both treatments are limited to relatively healthy patients due to safety and risk of death. Mickle K. et al., J Manag Care Spec Pharm. 2019; 25(1): 10-14. The price of clofazodone is also prohibitively high. Gilad A. et al., JACC May 11, 2021; Volume 77, Issue 18.
[0008] The use of small interfering RNA (siRNA) (such as patisiran), antisense oligonucleotides (inotersin), or monoclonal antibodies that target amyloid fibrils for destruction is relatively new. Although the results of short-term inhibition of TTR expression have shown encouraging preliminary data, there is still a need for treatments that can produce long-term inhibition of TTR. Therefore, effective and durable ATTR therapies are urgently needed. Summary of the invention
[0009] The present application relates to compositions and methods for knocking out TTR gene expression using a CRISPR / Cas system, thereby significantly reducing or eliminating the production of mutant TTR protein or wild-type TTR protein in the liver and circulation. The present application is based at least in part on the following discovery: a novel guide RNA (gRNA) with high editing efficiency can knock out or knock down mutant or wild-type TTR gene expression, thereby providing a durable treatment for ATTR.
[0010] In the first aspect, the present application describes a guide RNA comprising: a. a sequence selected from SEQ ID NO: 1-47; b. at least 15, 16, 17, 18, 19 or 20 consecutive nucleotides of a sequence selected from SEQ ID NO: 1-47; or c. a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a sequence selected from SEQ ID NO: 1-47.
[0011] In a second aspect, the present application describes a guide RNA comprising: a. a sequence selected from SEQ ID NO:48-81 or SEQ ID NO:275-307; b. at least 18, 19 or 20 consecutive nucleotides of a sequence selected from SEQ ID NO:48-81 or SEQ ID NO:275-307; or c. a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a sequence selected from SEQ ID NO:48-81 or SEQ ID NO:275-307.
[0012] In a third aspect, the present application describes a vector comprising one or more nucleic acids encoding one or more guide RNAs, wherein the one or more guide RNAs comprise: Ia one or more sequences selected from SEQ ID NOs: 1-47; Ib at least 15, 16, 17, 18, 19 or 20 consecutive nucleotides of one or more sequences selected from SEQ ID NOs: 1-47; or Ic one or more sequences that are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a sequence selected from SEQ ID NOs: 1-47; or II.a. one or more sequences selected from SEQ ID NOs: 48-81 or SEQ ID NOs: 275-307; II.b. at least 18, 19 or 20 consecutive nucleotides of one or more sequences selected from SEQ ID NOs: 48-81 or SEQ ID NOs: 275-307; or II.c. one or more sequences, each of which is identical to a sequence selected from SEQ ID NOs: 48-81 or SEQ ID NOs: The sequences of NOs: 275-307 are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical.
[0013] In a fourth aspect, the present application describes a composition comprising: (i) a nucleic acid encoding a guide RNA, or a vector comprising a nucleic acid encoding a guide RNA, wherein the guide RNA comprises: Ia a sequence selected from SEQ ID NOs: 1-47; Ib at least 15, 16, 17, 18, 19 or 20 consecutive nucleotides of a sequence selected from SEQ ID NOs: 1-47; or Ic a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a sequence selected from SEQ ID NOs: 1-47; or II.a. a sequence selected from SEQ ID NOs: 48-81 or SEQ ID NOs: 275-307; II.b. at least 18, 19 or 20 consecutive nucleotides of a sequence selected from SEQ ID NOs: 48-81 or SEQ ID NOs: 275-307; or II.c. a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a sequence selected from SEQ ID NOs: 48-81 or SEQ ID NOs: 275-307. NO:275-307 is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence of NO:275-307; and (ii) an RNA-guided DNA binder, a nucleic acid encoding an RNA-guided DNA binder, or a vector comprising a nucleic acid encoding an RNA-guided DNA binder.
[0014] In a fifth aspect, the present application describes a method for modifying a human transthyretin (TTR) gene and / or inducing a double-strand break (DSB) within a TTR gene, comprising administering a composition of the present application to a cell, wherein the composition recognizes and cleaves a TTR target sequence.
[0015] In a sixth aspect, the present application describes a method of reducing a subject's TTR serum concentration, reducing or preventing the deposition of amyloid protein or amyloid fibrils in a subject, and / or treating a subject's transthyretin amyloidosis (ATTR), comprising administering a composition of the present application to cells of a subject in need thereof, wherein the composition recognizes and cleaves the TTR target sequence, thereby reducing the subject's TTR serum concentration, reducing or preventing the deposition of amyloid protein or amyloid fibrils in the subject, and / or treating the subject's transthyretin amyloidosis (ATTR).
[0016] In some embodiments, the RNA-guided DNA binder comprises a Cas nuclease or a Cas nickase. In some embodiments, the guide RNA is a hybrid DNA-RNA guide. In some embodiments, the hybrid DNA-RNA guide comprises a sequence selected from SEQ ID NOs: 302 and 303. In some embodiments, the nucleic acid encoding the RNA-guided DNA binder is a Cas9 nucleic acid comprising the amino acid sequence shown in SEQ ID NO: 273 or 274. In some embodiments, the RNA-guided DNA binder is a Cas9 comprising the amino acid sequence shown in SEQ ID NO: 272. In some embodiments, the Cas nuclease is a Class 2 Cas nuclease. In some embodiments, the Cas nuclease is Cas9, Cpfl, C2cl, C2c2, and C2c3, or a modified protein thereof. In some embodiments, the Cas nuclease is a Streptococcus pyogenes or Staphylococcus aureus Cas9 nuclease or a modified protein thereof. In some embodiments, the Cas nuclease is from a Type II CRISPR / Cas system. In some embodiments, the Cas nuclease is fused to an exonuclease. In some embodiments, the exonuclease is selected from the group consisting of TREX1, TREX2 and MRE11. In some embodiments, the exonuclease is a truncated exonuclease. In some embodiments, the Cas nuclease is fused to the exonuclease at the C-terminus via a GGGGS linker.
[0017] In some embodiments, the composition of the present application is used to edit the transthyretin (TTR) gene. In some embodiments, editing is calculated as the percentage of edited cell populations (editing percentage). In some embodiments, about 30% to 99% of cell populations are edited. In some embodiments, the editing percentage is 30% to 35%, 35% to 40%, 40% to 45%, 45% to 50%, 50% to 55%, 55% to 60%, 60% to 65%, 65% to 70%, 70% to 75%, 75% to 80%, 80% to 85%, 85% to 90%, 90% to 95% or 95% to 99% of cell populations.
[0018] In some embodiments, the composition of the present application reduces the deposition of amyloid in at least one tissue or organ. In some embodiments, the tissue or organ is liver, stomach, colon, sciatic nerve or dorsal root ganglion. In some embodiments, amyloid deposition is measured 8 weeks after the composition is administered. In some embodiments, amyloid deposition is compared with a negative control or the level measured in the subject before the composition is administered. In some embodiments, amyloid deposition is reduced by at least 20% relative to the corresponding negative control or the level measured in the subject before the composition is administered.
[0019] In some embodiments, the composition is administered or delivered at least once. In some embodiments, administration or delivery is performed at intervals of: (a) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 days; (b) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 weeks; or (c) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 months.
[0020] In some embodiments, the guide RNA is at least partially complementary to a target sequence present in a human TTR gene. In some embodiments, the target sequence is located in exon 1, 2, 3, or 4 of a human TTR gene. In some embodiments, the guide RNA sequence is complementary to a target sequence in the positive strand of a TTR gene. In some embodiments, the guide RNA sequence is complementary to a target sequence in the negative strand of a TTR gene. In some embodiments, the first guide sequence is complementary to a first target sequence in the positive strand of a TTR gene, and wherein the composition further comprises a second guide sequence complementary to a second target sequence in the negative strand of a TTR gene.
[0021] In some embodiments, the guide RNA comprises crRNA, and further comprises tracrRNA or a portion thereof, wherein the tracrRNA (trRNA) comprises the nucleotide sequence shown in SEQ ID NO: 257, wherein the trRNA is operably linked to the crRNA.
[0022] In some embodiments, the guide RNA is a dual guide RNA (dgRNA). In some embodiments, the guide RNA is a single guide RNA (sgRNA). In some embodiments, the guide RNA comprises at least one modification. In some embodiments, the at least one modification includes 2'-O-methyl (2'-O-Me) modified nucleotides, phosphorothioate (PS) bonds between nucleotides, or 2'-fluoro (2'-F) modified nucleotides. In some embodiments, the at least one modification includes modification of one or more of the first five nucleotides at the 5' end of the guide RNA and / or at one or more of the last five nucleotides at the 3' end of the guide RNA. In some embodiments, the at least one modification includes modification of at least 50% of the nucleotides of the guide RNA.
[0023] In some embodiments, the sgRNA comprises a guide sequence that is at least 90% identical to a sequence selected from SEQ ID NO: 1-81 or SEQ ID NO: 275-307. In some embodiments, the sgRNA comprises a nucleotide sequence set forth in any one of SEQ ID NO: 171-251 or SEQ ID NO: 341-373. In some embodiments, the sgRNA comprises a nucleotide sequence that is at least 90% identical to a nucleotide sequence set forth in any one of SEQ ID NO: 171-251 or SEQ ID NO: 341-373. In some embodiments, at least a portion of the sgRNA is a hybrid DNA-RNA guide. In some embodiments, the sgRNA comprises a nucleotide sequence set forth in any one of SEQ ID NO: 368-369.
[0024] In some embodiments, the guide RNA is associated with a lipid nanoparticle (LNP).In some embodiments, the composition is a pharmaceutical formulation and further comprises a pharmaceutically acceptable carrier.
[0025] In some embodiments, the composition comprises: (i) a nucleic acid encoding a guide RNA or a vector comprising a nucleic acid encoding a guide RNA, and (ii) an mRNA encoding an RNA-guided DNA binder, which is associated with a lipid nanoparticle (LNP). In some embodiments, the LNP comprises ALC0315, DSPC, cholesterol, and DMG-PEG2000. In some embodiments, the N / P ratio of the LNP is about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, the N / P ratio is about 3-7. In some embodiments, ALC0315 accounts for 40% to 60% of the total lipids present in the particle, DSPC accounts for 5% to 15% of the total lipids present in the particle, cholesterol accounts for 30% to 50% of the total lipids present in the particle, and DMG-PEG2000 accounts for 1% to 5% of the total lipids present in the particle. In some embodiments, the LNP comprises ALC0315, DSPC, cholesterol, and DMG-PEG2000 in a molar ratio of 50:9.5:37.5:3.
[0026] In some embodiments, the composition reduces or prevents amyloid deposition and / or formation of amyloid fibrils. In some embodiments, amyloid deposition and / or formation of amyloid fibrils are located in the nerves, heart, or gastrointestinal tract.
[0027] In some embodiments, administration of the composition results in a deletion or insertion of one or more nucleotides in the TTR gene. In some embodiments, the deletion or insertion of one or more nucleotides induces a frameshift or nonsense mutation in the TTR gene. In some embodiments, a frameshift or nonsense mutation is induced in the TTR gene of about 20% to about 30% of the cells. In some embodiments, the cell is a hepatocyte. In some embodiments, the deletion or insertion of one or more nucleotides occurring in the TTR gene is at least 50 times more than in the off-target site or more.
[0028] In some embodiments, the composition reduces the level of monomer, dimer and / or tetramer TTR in the subject. In some embodiments, the level of monomer, dimer and / or tetramer TTR is reduced by at least 30%. In some embodiments, the level of monomer, dimer and / or tetramer TTR is measured in serum, plasma, blood, or cerebrospinal fluid.
[0029] In some embodiments, the subject has wild-type ATTR (ATTRwt), inherited ATTR, a family history of ATTR, or familial amyloid polyneuropathy. In some embodiments, the subject exhibits neurological symptoms of ATTR. In some embodiments, the subject has familial amyloid cardiomyopathy. In some embodiments, the subject exhibits cardiac symptoms of ATTR.
[0030] In some embodiments, the subject expresses wild-type TTR or TTR with one or more mutations selected from the group consisting of V28S, F33V, F33L, K35N, K35T, A36P, D38V, E42G, G47R, G47V, G47E, T49A, S50R, G53E, E54K, E54G, E54Q, T59K, E61K, Y69H, S77Y, S77F, G83R, A97S, Y114C, V30A, V30G, V30L, V30M, T60A, V122A, V122I, or V122(-). In some embodiments, the subject is homozygous for wild-type TTR.
[0031] In some embodiments, after administration of the composition of the present application, the subject exhibits improvement, stabilization, or slowing of changes in symptoms of sensory motor neuropathy. In some embodiments, electromyography, nerve conduction tests, or patient-reported results are used to measure improvement, stabilization, or slowing of changes in sensory neuropathy. In some embodiments, the subject exhibits improvement, stabilization, or slowing of changes in symptoms of congestive heart failure.
[0032] In some embodiments, the composition or pharmaceutical formulation is administered via a viral vector. In some embodiments, the composition or pharmaceutical formulation is administered via a lipid nanoparticle.
[0033] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this application belongs. Methods and materials for use in this application are described herein; other suitable methods and materials known in the art may also be used. The materials, methods, and examples are illustrative only and are not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In the event of a conflict, the present specification (including definitions) shall prevail.
[0034] Other features and advantages of the methods and materials described herein will be apparent from the following detailed description and drawings, and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 Shown are the editing efficiencies (editing %) of 15 different gRNAs in HEK293 cells electroporated with RNPs (ribonucleoproteins) containing spCas9 protein and synthetic sgRNAs.
[0036] Figure 2 Shown are the editing efficiencies (editing %) of 59 different gRNAs in HepG2 cells electroporated with RNPs (ribonucleoproteins) containing spCas9 protein and synthetic sgRNAs.
[0037] Figure 3 Figure 2 is a graph of editing efficiency (editing %) of sgRNAs targeting human TTR delivered to primary human hepatocytes from different donors using RNAi max. Guide sequences are ranked according to highest editing %. Figure 3 The graph corresponds to the data presented in Table 7.
[0038] Figure 4 Figure 2 is a graph of editing efficiency (editing %) of sgRNAs targeting human TTR delivered to primary human hepatocytes from different donors using RNAi max. Guide sequences are ranked according to highest editing %. Figure 4 The graph corresponds to the data presented in Table 8.
[0039] Figure 5 Figure 2 is a dose-response curve of the EC50 and maximum editing of the tested human-specific TTR sgRNA and Spy Cas9 protein on HepG2. Figure 5 The graph corresponds to the data presented in Table 9.
[0040] Figure 6Figure 2 is a dose-response curve of EC50 and maximal editing of HepG2 cells for the tested human-specific TTR sgRNA and Spy Cas9 mRNA formulated in LNP. Figure 6 The graph corresponds to the data presented in Table 10.
[0041] Figure 7 Figure 3 is a graph of the concentration response of the tested human-specific TTR sgRNA and Spy Cas9 mRNA formulated in LNPs for editing of primary human hepatocytes.
[0042] Figure 8 Figure 2 is a graph showing the percent reduction of TTR protein in primary human hepatocytes after transfection with sgRNA disclosed herein as measured by Western blotting. β-actin was used as a loading control.
[0043] Fig. 9 Figure 2 is a graph showing the percent reduction of TTR protein in primary human hepatocytes after transfection with sgRNA disclosed herein as measured by Western blotting. β-actin was used as a loading control.
[0044] Fig.10 is a graph of the percent reduction of TTR protein in primary human hepatocytes measured by ELISA after transfection with the sgRNA disclosed herein.
[0045] Fig.11 is a graph of the percent reduction of TTR protein in primary human hepatocytes measured by ELISA after transfection with the sgRNA disclosed herein.
[0046] Fig.12 is a graph of the editing efficiency of several sgRNAs disclosed herein after transfection of PHH cells with LNPs containing Cas9 mRNA and sgRNA. Fig.12 Dose-response curves for several sgRNAs are shown.
[0047] Fig.13 It is a graph of the editing efficiency of several sgRNAs disclosed in this article, showing the off-target amplicon sequencing results (amp-seq) of several sgRNAs at the maximum dose.
[0048] Fig.14 It is a graph of the editing efficiency of several sgRNAs disclosed in this article, showing the off-target amplicon sequencing results (amp-seq) of several sgRNAs at the maximum dose.
[0049] Fig.15 is a graph of targeted editing efficiencies for combinations of exonuclease fusions and sgRNA modifications for several modified sgRNAs and sgRNA fusions disclosed herein.
[0050] Fig.16 is a graph of off-target editing efficiencies for combinations of exonuclease fusions and sgRNA modifications for several modified sgRNAs and sgRNA fusions disclosed herein.
[0051] Fig.17 Graphs of off-target editing efficiency for combinations of exonuclease fusions and sgRNA modifications for several modified sgRNAs and sgRNA fusions disclosed herein.
[0052] Fig.18 Graph of serum TTR levels (μg / ml) in mice after treatment with an LNP composition containing sgRNA ART-001-g-066 and Cas9 mRNA (1:1 weight ratio). The LNP had an N:P ratio of 3 and contained ALC0315, DSPC, cholesterol, and PEG2k-DMG at a molar ratio of 50:10:38.5:1.5. Serum TTR was measured using ELISA.
[0053] Fig.19 Figure 2 is a graph of serum TTR levels (μg / ml) and TTR editing percentage in liver tissue of mice treated with LNP compositions containing sgRNA ART-001-g-066 and Cas9 mRNA (1:1 weight ratio). The dose levels were 3, 1, or 0.3 mg / kg.
[0054] Fig. 20A is a graph of serum TTR levels (μg / ml) in mice after treatment with an LNP composition containing sgRNA ART-001-g-066 and Cas9 mRNA (weight ratio of 1:1).
[0055] Fig. 20B is a graph of serum TTR levels (μg / ml) in mice after treatment with an LNP composition containing sgRNA ART-001-g-066 and Cas9 mRNA (weight ratio of 1:1).
[0056] Fig.21 is a graph of serum TTR levels (μg / ml) in mice after treatment with several doses of LNP compositions containing sgRNA ART-001-g-066 and Cas9 mRNA (weight ratio of 1:1 or 1:2). CD-1 female mice were intravenously dosed at 0.1, 0.3, and 1 mg / kg.
[0057] Fig. 22 is a graph of serum TTR levels (μg / ml) in mice after treatment with LNPs containing different amine lipids. LNPs were formulated with guide RNA ART-001-g-067. CD-1 female mice were dosed intravenously at a dose of 0.3 mg / kg.
[0058] Fig.23 is a graph of normalized human protein (%) in the serum of humanized TTR V30M knock-in mice after treatment with several sgRNAs disclosed herein.
[0059] Fig.24 is a graph of normalized human protein (%) in the serum of humanized TTR V30M knock-in mice after treatment with several sgRNAs disclosed herein. The dose level was 1 or 3 mg / kg.
[0060] Fig.25A Graph showing the percentage of TTR knockdown after treatment of TTR humanized mice with a composition of LNPs containing several mixed DNA-RNA sgRNAs disclosed herein. The doses were 0.1, 0.3, and 0.6 mg / kg.
[0061] Fig.25B Graph showing the percentage of TTR knockdown after treatment of TTR humanized mice with a composition of LNPs containing several mixed DNA-RNA sgRNAs disclosed herein. The doses were 0.1, 0.3, and 0.6 mg / kg. DETAILED DESCRIPTION
[0062] The present application describes compositions and methods for editing the human transthyretin (TTR) gene. The compositions and methods described herein are used to treat subjects suffering from transthyretin-associated amyloidosis (ATTR).
[0063] Before describing the present teachings in detail, it should be understood that the application is not limited to specific compositions or process steps, as these may vary. It should be noted that as used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a conjugate" includes a plurality of conjugates, reference to "a cell" includes a plurality of cells, and so forth.
[0064] definition
[0065] Unless otherwise stated, the following terms and phrases used herein shall have the following meanings:
[0066] As used herein, the term "nucleic acid" refers to a polymer compound having nucleosides or nucleoside analogs having nitrogenous heterocyclic bases or base analogs linked together along the backbone, including conventional RNA, DNA, mixed RNA-DNA, and polymers as analogs thereof. The terms "nucleic acid", "polynucleotide", "nucleotide", "nucleotide sequence", and "oligonucleotide" are used interchangeably. They refer to a polymeric form of nucleotides of any length, whether deoxyribonucleotides or ribonucleotides, or analogs thereof. The following are non-limiting examples of nucleic acids: coding regions or non-coding regions of genes or gene fragments, loci defined by linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short hairpin RNA (shRNA), micro RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers. The term also encompasses nucleic acid-like structures with synthetic backbones, see, e.g., Eckstein, 1991; Baserga et al., 1992; Milligan, 1993; WO 97 / 03211; WO 96 / 39154; Mata, 1997; Strauss-Soukup, 1997; and Samstag, 1996. A polynucleotide may contain one or more modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, the nucleotide structure may be modified before or after polymer assembly. The nucleotide sequence may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.
[0067] The nucleic acid backbone can be composed of a variety of bonds, including one or more of a sugar-phosphodiester bond, a peptide-nucleic acid bond ("peptide nucleic acid" or PNA, such as those described in International Patent Publication No. WO1995032305), a phosphorothioate bond, a methylphosphonate bond, or a combination thereof. The sugar portion of the nucleic acid can be ribose, deoxyribose, or a similar compound having a substituent (e.g., 2' methoxy or 2' halide substitution). The nitrogenous base can be a conventional base (A, G, C, T, U), an analog thereof (e.g., a modified uridine such as 5-methoxyuridine, pseudouridine or N1-methylpseudouridine, etc.); inosine; a derivative of a purine or pyrimidine (e.g., N4-methyldeoxyguanosine, a deaza or azapurine, a deaza or azapyrimidine, a pyrimidine base having a substituent at the 5 or 6 position (e.g., 5-methylcytosine), a purine base having a substituent at the 2, 6 or 8 position, 2-amino-6-methylaminopurine, 06-methylguanine, 4-thiopyrimidine, 4-aminopyrimidine, 4-dimethylhydrazinepyrimidine and 04-alkylpyrimidine; (see, e.g., U.S. Pat. No. 5,378,825 and International Patent Publication No. WO1993013121). For a general discussion, see The Biochemistry of the Nucleic Acids 5-36, Adams et al., ed., 11th ed., 1992). Nucleic acids may include one or more "absic" residues, in which the backbone does not include a nitrogenous base at one or more positions of the polymer (see, e.g., U.S. Pat. No. 5,585,481). Nucleic acids may contain only conventional RNA or DNA sugars, bases, and bonds, or may include conventional components and substitutes (e.g., conventional bases with 2' methoxy bonds, or polymers containing both conventional bases and one or more base analogs). Nucleic acids include "locked nucleic acids" (LNA), which are analogs containing one or more LNA nucleotide monomers in which the bicyclic furanose unit is locked in an RNA-mimicking sugar conformation, thereby enhancing hybridization affinity for complementary RNA and DNA sequences (Vester and Wengel, 2004, Biochemistry 43 (42): 13233-41). RNA and DNA have different sugar moieties and may differ by the presence of uracil or its analogs in RNA and thymine or its analogs in DNA.
[0068] As used herein, the term "guide RNA" refers to a combination of CRISPR RNA (crRNA) and tracr RNA (trRNA). "Guide RNA" can be used interchangeably with "gRNA" or "guide". CrRNA and trRNA can be associated as a single RNA molecule (single guide RNA, sgRNA) or in two separate RNA molecules (dual guide RNA, dgRNA). "Guide RNA" or "gRNA" can refer to each type, i.e., sgRNA or dgRNA. TrRNA can be a naturally occurring sequence, or the trRNA sequence can have a modification or variation compared to a naturally occurring sequence. Guide RNA can include modified RNA as described herein.
[0069] As used herein, "guide sequence" refers to a sequence within a guide RNA that is complementary to a target sequence and is used to guide the guide RNA to the target sequence for binding or modification (e.g., cleavage) by an RNA-guided DNA binder. "Guide sequence" may also be referred to as a "targeting sequence" or a "spacer sequence". The guide sequence may be about 20 base pairs in length, for example, in the case of Streptococcus pyogenes (i.e., Spy Cas9) and related Cas9 homologs / orthologs. Shorter or longer sequences may also be used as guide sequences, for example, with a length of 15, 16, 17, 18, 19, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the guide sequence and the targeting sequence may be 100% complementary or identical to each other in sequence. In other embodiments, the guide sequence and the targeting sequence may include at least one mismatch. For example, the guide sequence and the targeting sequence may include 1, 2, 3, or 4 mismatches, wherein the total length of the targeting sequence is at least 17, 18, 19, 20, or more base pairs. In some embodiments, the guide sequence and the targeting sequence may comprise 1-4 mismatches, wherein the guide sequence comprises at least 17, 18, 19, 20, or more nucleotides. In some embodiments, the guide sequence and the targeting sequence may comprise 1, 2, 3, or 4 mismatches, wherein the guide sequence comprises at least 20 nucleotides.
[0070] In some embodiments, the guide RNA comprises a crRNA having a guide sequence (e.g., a guide sequence from Table 3) and further comprises a nucleotide sequence GUU UUA GAG CUA UGC UGU UUU G (SEQ ID NO: 256), wherein SEQ ID NO: 256 is immediately adjacent to the 3' end of the guide sequence. In some embodiments, the crRNA is any crRNA selected from the nucleotide sequences shown in SEQ ID NO: 86-166 or SEQ ID NO: 308-340. In some embodiments, the guide RNA comprises any crRNA nucleotide sequence shown in SEQ ID NO: 86-166 or SEQ ID NO: 308-340.
[0071] In some embodiments, the guide RNA comprises a crRNA and further comprises a tracrRNA (trRNA) sequence comprising the nucleotide sequence shown in SEQ ID NO: 257 or a portion thereof. AAC AGC AUA GCA AGU UAA AAU AAG GCUAGU CCG UUA UCA ACU UGA AAA AGU GGC ACC GAG UCG GUG CUU UUU UU (SEQ ID NO: 257).
[0072] In some embodiments, the guide RNA comprises additional nucleotides to form an sgRNA, for example, having the following exemplary nucleotide sequence after the 3' end of the guide sequence: GUU UUA GAG CUA GAA AUA GCA AGU UAA AAU AAGGCU AGU CCG UUA UCA ACU UGA AAA AGU GGC ACC GAG UCG GUG CUU UU (SEQ ID NO: 258), in a 5' to 3' direction. In some embodiments, the sgRNA is any sgRNA selected from the nucleotide sequences shown in SEQ ID NOs: 171-251 or SEQ ID NOs: 341-373. In some embodiments, the gRNA comprises any one of the nucleotide sequences shown in SEQ ID NOs: 171-251 or SEQ ID NOs: 341-373. In some embodiments, the gRNA consists of any one of the nucleotide sequences shown in SEQ ID NOs: 171-251 or SEQ ID NOs: 341-373.
[0073] In some embodiments, the guide RNA comprises a portion of SEQ ID NO: 256 covalently linked to a trRNA. For example, a guide RNA comprises a guide sequence (e.g., a guide sequence from Table 3) linked to GUUUUAGAGCUA (SEQ ID NO: 259), which is further linked to a trRNA (SEQ ID NO: 257 or a portion thereof). For example, a guide RNA comprises a guide sequence (e.g., a guide sequence from Table 3) linked to GUU UUA GAG CUA (SEQ ID NO: 259), which is further linked to the nucleotide sequence AUA GCA AGU UAA AAU AAG GCU AGU CCG UUA UCA ACU UGA AAA AGU GGC ACCGAG UCG GUG CUU UU (SEQ ID NO: 260).
[0074] The targeting sequence of the Cas protein includes the positive and negative strands of the genomic DNA (i.e., a given sequence and the reverse complementary sequence of the sequence) because the nucleic acid substrate of the Cas protein is double-stranded. Therefore, when the guide sequence is referred to as "complementary to the target sequence", it should be understood that the guide sequence can guide the guide RNA to bind to the reverse complementary sequence of the target sequence. Therefore, in some embodiments in which the guide sequence binds to the reverse complementary sequence of the target sequence, in addition to replacing T with U in the guide sequence, the guide sequence is identical to certain nucleotides of the target sequence (e.g., a target sequence excluding the protospacer adjacent motif (PAM)).
[0075] As used herein, "RNA-guided DNA binder" refers to a polypeptide or polypeptide complex having RNA and DNA binding activity, or a DNA binding subunit of such a complex, wherein the DNA binding activity is sequence-specific and depends on the sequence of the RNA. Exemplary RNA-guided DNA binders (such as those described in International Patent Application No. WO2020198697, the entire contents of which are incorporated herein) include Cas nickases and inactivated forms thereof, such as dCas DNA binders".
[0076] As used herein, the term "Cas" refers to any Cas protein that can be operably used to perform gene editing using a guide molecule. "Cas nuclease" also covers Cas nickases, and endonuclease-deficient or inactivated Cas (dCas) DNA binders. Cas nickases and dCas DNA binders can include Csm or Cmr complexes of type III CRISPR systems, its Cas10, Csml or Cmr2 subunits, Cascade complexes of type I CRISPR systems, its Cas3 subunits, and 2 types of Cas nucleases. As used herein, "2 types of Cas nucleases" are single-chain polypeptides with RNA-guided DNA binding activity, such as Cas9 nucleases or Cpf1 nucleases. 2 types of Cas nucleases include 2 types of Cas nickases (e.g., H840A, D10A or N863A variants), which also have RNA-guided DNA nickase activity, and 2 types of dCas DNA binders, wherein the nickase activity is inactivated. Class 2 Cas nucleases include, for example, Cas9, Cpf1, C2cl, C2c2, C2c3, HF Cas9 (e.g., N497A, R661A, Q695A, Q926A variants), HypaCas9 (e.g., N692A, M694A, Q695A, H698A variants), eSPCas9 (1.0) (e.g., K810A, K1003A, R1060A variants), and eSPCas9 (1.1) (e.g., K848A, K1003A, R1060A variants) proteins and modifications thereof. Cpf1 protein, Zetsche et al., Cell, 163: 1-13 (2015), is homologous to Cas9 and contains a RuvC-like nuclease domain. Zetsche's Cpf1 sequence is incorporated by reference in its entirety. See, e.g., Zetsche, Tables SI and S3. "Cas9" encompasses Spy Cas9, the Cas9 variants listed herein, and their equivalents. See, e.g., Makarova et al., Nat Rev Microbiol, 13(11):722-36 (2015); Shmakov et al., Molecular Cell, 60:385-397 (2015).
[0077] dCas DNA binders can be used for CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa). In CRISPRi, dCas9 binds to its DNA target but does not cleave it. Without being bound by theory, it is believed that Cas9 alone will prevent the cell's transcription machinery from approaching the promoter, thereby inhibiting gene expression. On the other hand, the ability of dCas9 to bind to target DNA can be used for activation, i.e. CRISPRa. Transcription activators are fused to dCas9, which can activate gene expression without changing the DNA sequence. In some embodiments, dCas DNA binders are fused to repressors, such as Krüppel-associated boxes (KRAB).
[0078] "Modified uridine" as used herein refers to a nucleoside having the same hydrogen bond acceptor as uridine and having one or more structural differences with uridine. In some embodiments, the modified uridine is a substituted uridine, i.e., a uridine in which one or more non-proton substituents (e.g., an alkoxy group, such as a methoxy group) replace a proton. In some embodiments, the modified uridine is a pseudouridine. In some embodiments, the modified uridine is a substituted pseudouridine, i.e., a pseudouridine in which one or more non-proton substituents (e.g., an alkyl group, such as a methyl group) replace a proton, e.g., N1-methyl pseudouridine. In some embodiments, the modified uridine is any one of a substituted uridine, a pseudouridine, or a substituted pseudouridine.
[0079] As used herein, a first sequence is said to "comprise a sequence at least X% identical to a second sequence" if an alignment of the first sequence with a second sequence shows that X% or more of the positions in the second sequence as a whole match the first sequence. For example, the sequence AAGA comprises a sequence that has 100% identity to the sequence AAG, since the alignment would yield 100% identity due to matches to all three positions in the second sequence. Differences between RNA and DNA (typically the exchange of uridine for thymidine or vice versa) and the presence of nucleoside analogs (such as modified uridine) do not result in differences in identity or complementarity between polynucleotides, as long as related nucleotides (such as thymidine, uridine or modified uridine) are bound to the same complementary nucleotide (e.g., adenosine is the complement of all thymidine, uridine or modified uridine; another example is cytosine and 5-methylcytosine, both of which have guanosine or modified guanosine as a complement). Thus, for example, the sequence 5'-AXG (wherein X is any modified uridine, such as pseudouridine, N1-methylpseudouridine or 5-methoxyuridine) is considered to be 100% identical to AUG, since both are fully complementary to the same sequence (5'-CAU). Exemplary alignment algorithms are the Smith-Waterman and Needleman-Wunsch algorithms, which are well known in the art. One skilled in the art will understand which algorithm and parameter settings are appropriate for a given pair of sequences to be aligned; for sequences that are generally similar in length and have an expected identity of >50% for amino acids or >75% for nucleotides, the Needleman-Wunsch algorithm using the default settings of the Needleman-Wunsch algorithm interface provided by EBI on the www.ebi.ac.uk web server is generally appropriate.
[0080] As used herein, the term "mRNA" refers to a polynucleotide that is an RNA or modified RNA that includes an open reading frame that can be translated into a polypeptide (i.e., can serve as a substrate for translation by ribosomes and aminoacylated tRNAs). The mRNA may include a phosphate-sugar backbone having a ribose residue or an analog thereof (e.g., a 2'-methoxyribose residue). In some embodiments, the sugar of the nucleic acid phosphate-sugar backbone consists essentially of a ribose residue, a 2'-methoxyribose residue, or a combination thereof.
[0081] As used herein, the term "TTR" refers to transthyretin, which is the expression product of the TTR gene. The human wild-type TTR sequence is available at NCBI Gene ID: 7276; Ensembl: Ensembl: ENSG00000118271. Transthyretin is a 56kDa non-glycosylated protein consisting of four identical 127 amino acid subunits. The single-copy transthyretin gene is located on chromosome 18 and consists of four exons spanning 7300 base pairs. The 5'-flanking region has a highly homologous DNA sequence across species, indicating that it plays a vital role in regulating transthyretin gene expression. Transthyretin is mainly derived from the liver in rats and humans, but is also synthesized in pancreatic islet cells, retina, and choroid plexus epithelial cells. As used herein, "mutant TTR" refers to a TTR gene product (i.e., TTR protein) having a change in the amino acid sequence of TTR compared to the wild-type amino acid sequence of TTR. Mutated forms of TTR related to ATTR (e.g., in humans) include V30M, V30A, V30G, V30L, T60A, V122I, V122A, or V122(-).
[0082] As used herein, "amyloid" refers to abnormal aggregates of normally soluble proteins or peptides. Amyloid is insoluble, and amyloid can produce protein deposits in organs and tissues. The protein or peptide in amyloid may be misfolded into a form that causes many copies of the protein to stick together to form fibrils. Although some forms of amyloid may have normal functions in the human body, "amyloid" as used herein refers to abnormal or pathological aggregates of proteins. Amyloids can contain a single protein or peptide, such as TTR, or they can contain multiple proteins or peptides, such as TTR and other proteins.
[0083] As used herein, "amyloid fibrils" refer to insoluble fibers of amyloid protein that are not easily degraded. Amyloid fibrils can produce symptoms depending on the specific protein or peptide and the tissue and cell type in which they aggregate.
[0084] As used herein, "amyloidosis" refers to a disease characterized by symptoms caused by the deposition of amyloid protein or amyloid fibrils. Amyloidosis can affect a variety of organs, including the heart, kidneys, liver, spleen, nervous system, and digestive tract.
[0085] As used herein, "ATTR," "ATTR amyloidosis," or "TTR-related amyloidosis" refers to amyloidosis that occurs due to the deposition of TTR amyloid fibrils.
[0086] As used herein, "familial amyloid cardiomyopathy" or "FAC" refers to a hereditary transthyretin amyloidosis (ATTR) whose primary feature is restrictive cardiomyopathy. Congestive heart failure is common in FAC. The average age of onset is approximately 60-70 years, and life expectancy after diagnosis is estimated to be 4-5 years.
[0087] As used herein, "familial amyloid polyneuropathy" or "FAP" refers to a hereditary transthyretin amyloidosis (ATTR) whose primary feature is sensory motor neuropathy. Autonomic neuropathy is common in FAP. Although neuropathy is the primary feature, symptoms of FAP can also include cachexia, renal failure, and heart disease. The average age of onset of FAP is approximately 30-50 years, and the life expectancy after diagnosis is estimated to be 5-15 years.
[0088] As used herein, "wild-type ATTR" and "ATTRwt" refer to ATTR that is not associated with a pathological TTR mutation such as T60A, V30M, V30A, V30G, V30L, V122I, V122A, or V122(-). ATTRwt is also known as senile systemic amyloidosis. Onset usually occurs in men aged 60 years or older, and the most common symptoms are congestive heart failure and arrhythmias (such as atrial fibrillation). Other symptoms include the consequences of poor heart function, such as shortness of breath, fatigue, dizziness, swelling (especially in the legs), nausea, angina, disrupted sleep, and weight loss. A history of carpal tunnel syndrome indicates an increased risk for ATTRwt and may indicate an early stage of the disease in some cases. ATTRwt typically causes a decline in heart function over time, but the prognosis may be better than inherited ATTR because wild-type TTR deposits accumulate more slowly. Existing treatments are similar to those for other forms of ATTR (except for liver transplantation) and are generally aimed at supporting or improving heart function, ranging from the use of diuretics and restriction of fluid and salt intake to the use of anticoagulants and, in severe cases, even heart transplantation. Nevertheless, like FAC, ATTRwt can also lead to death from heart failure, sometimes within 3-5 years of diagnosis.
[0089] As used herein, "hereditary ATTR" refers to ATTR associated with a mutation in the TTR gene sequence. Known mutations of the TTR gene associated with ATTR include mutations that cause TTR to undergo T60A, V30M, V30A, V30G, V30L, V122I, V122A, or V122(-) substitutions. Other mutations include V28S, F33V, F33L, K35N, K35T, A36P, D38V, E42G, G47R, G47V, G47E, T49A, S50R, G53E, E54K, E54G, E54Q, T59K, E61K, Y69H, S77Y, S77F, G83R, A97S, or Y114C.
[0090] As used herein, the term "pathological mutation" refers to a mutation that makes a gene product (such as TTR) more likely to cause, promote, contribute to, or fail to suppress the development of a disease (such as ATTR).
[0091] As used herein, "indel" refers to an insertion / deletion mutation consisting of several nucleotides inserted or deleted at the double-strand break (DSB) site of the target nucleic acid.
[0092] As used herein, "knock down" refers to the reduction of expression of a specific gene product (e.g., protein, mRNA or both). The knock down of a protein can be measured by detecting the protein secreted by a tissue or cell group (e.g., in serum or cell culture medium) or by detecting the total cell amount of the protein from the tissue or cell group of interest before and after the knock down. The method for measuring mRNA knockdown is known in the art, and includes sequencing the mRNA separated from the tissue or cell group of interest. In some embodiments, "knock down" can refer to some losses of expression of a specific gene product, for example, the amount of transcribed mRNA is reduced or the amount of protein expressed or secreted by a cell group (including a cell group in vivo, such as a cell group found in a tissue) is reduced.
[0093] As used herein, "target sequence" refers to a nucleic acid sequence in a target gene that is complementary to the guide sequence of a gRNA. The interaction of the target sequence and the guide sequence guides the RNA-guided DNA binder to bind within the target sequence and may produce a nick or cleavage within the target sequence (depending on the activity of the binder).
[0094] As used herein, "treating" or "treatment" means that at least one symptom of a disclosed condition is improved, alleviated, or relieved following administration or application of a therapeutic agent for the condition. The term includes inhibiting the condition or disease, arresting its development, alleviating one or more symptoms of the condition or disease, curing the condition or disease, or preventing the recurrence of one or more symptoms of the condition or disease. In the context of the present application, treatment of ATTR may include alleviating symptoms of ATTR. If the treatment results in a reduction in the pathology of the condition (e.g., amyloid deposition), then treatment using the compositions of the present application is said to have "treated" the condition.
[0095] As used herein, the term "lipid nanoparticle" (LNP) refers to a particle comprising a plurality (i.e., more than one) of lipid molecules that are physically associated with each other by intermolecular forces. LNPs can be, for example, microspheres (including unilamellar and multilamellar vesicles, such as "liposomes" - lamellar phase lipid bilayers, in some embodiments, substantially spherical - and in more specific embodiments, can include an aqueous core, for example, including a majority of RNA molecules), a dispersed phase in an emulsion, an internal phase in a micelle or a suspension. See also, for example, WO2015006747, WO2016118724, WO2021026358, WO2017173054, and WO2019067992, the contents of which are incorporated herein by reference in their entirety. Any LNP known to those skilled in the art capable of delivering nucleotides to a subject can be used with guide RNA and nucleic acids encoding RNA-guided DNA binders described herein.
[0096] As used herein, the term "pharmaceutically acceptable" refers to a biologically acceptable gaseous, liquid or solid formulation, or a mixture thereof, which is suitable for one or more routes of administration, in vivo delivery or contact. A "pharmaceutically acceptable" composition is a material that does not cause biological or other adverse effects, for example, the material can be administered to a subject without causing significant adverse biological effects.
[0097] As used herein, "infusion" refers to the active administration of one or more agents, and the infusion time is, for example, about 30 minutes to 12 hours. In some embodiments, the one or more agents include LNPs, such as mRNA encoding an RNA-guided DNA binder (such as Cas9) described herein and a gRNA described herein.
[0098] The terms "about" or "approximately" mean an acceptable error for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined.
[0099] Numerical ranges include the numbers defining the range. Taking into account significant figures and errors associated with measurement, measured values and measurable values should be understood as approximate values. In addition, the use of "comprise, comprises, comprising", "contain, contains, containing" and "include, includes, including" is not intended to be limiting. It should be understood that the foregoing general description and detailed description are only exemplary and explanatory and do not limit the teaching.
[0100] Unless otherwise specified in the above description, the embodiments described in the description "including" various components should also be understood as "consisting of the components" or "consisting essentially of the components"; the embodiments described in the description "consisting of various components" should also be understood as "including" or "consisting essentially of the components"; the embodiments described in the description "consisting essentially of various components" should also be understood as "consisting of the components" or "including" the components (this interchangeability does not apply to the use of these terms in the claims). Unless the context clearly indicates otherwise, the term "or" is used in an inclusive sense, that is, equivalent to "and / or".
[0101] Compositions and methods targeting the TTR gene
[0102] Disclosed herein are compositions for methods of targeting the TTR gene. The methods disclosed herein induce double-strand breaks (DSBs) in the TTR gene of a subject, modify the TTR gene of a cell or subject, treat TTR-related amyloidosis (ATTR) in a subject, reduce serum concentrations of TTR monomers, dimers and / or tetramers in a subject, and / or reduce or prevent the accumulation of amyloid or amyloid fibrils in a subject. In some embodiments, the disclosed compositions and methods inhibit the transcription and translation of TTR, thereby preventing the accumulation of TTR in tissues. In general, the disclosed compositions include: a guide RNA targeting TTR (either by itself or in a vector), and an RNA-guided DNA binder, or a nucleic acid encoding an RNA-guided DNA binder (e.g., a CRISPR / Cas system). Subjects treated with such methods and compositions may have a wild-type or non-wild-type TTR gene sequence, such as, for example, a subject with ATTR, which may be ATTR wt or a hereditary or familial form of ATTR. In some embodiments, the composition is administered by infusion for 0.5-6 hours. In some embodiments, the composition is administered by subcutaneous injection. In some embodiments, the composition is administered by intrathecal injection.
[0103] A. Guide RNA (gRNA)
[0104] The guide RNA used in the disclosed methods and compositions comprises a guide sequence that targets the TTR gene. Exemplary guide sequences that target the TTR gene are shown in Table 3 as SEQ ID NOs: 1-85 and SEQ ID NOs: 275-307. Guide sequences useful in the guide RNA compositions and methods described herein are shown in Table 3 and throughout the application.
[0105] Each guide sequence in Table 3 may further comprise additional nucleotides to form a crRNA, for example, the following exemplary nucleotide sequence is immediately followed at the 3' end of the guide sequence: GUU UUA GAG CUA UGC UGU UUU G (SEQ ID NO: 256). In the case of sgRNA, the guide sequence of Table 3 may further comprise additional nucleotides to form an sgRNA, for example, the following exemplary nucleotide sequence is immediately followed at the 3' end of the guide sequence, wherein the sgRNA has a custom-designed short crRNA component followed by a trRNA component: GUU UUA GAG CUA GAA AUA GCA AGU UAA AAU AAG GCU AGU CCG UUA UCA ACUUGA AAA AGU GGC ACC GAG UCG GUG CUU UU (SEQ ID NO: 258), in a 5' to 3' direction.
[0106] SEQ ID NO: 258 is attached to the 3' end of the guide sequence in a 5' to 3' direction. sgRNA sequences useful in the compositions and methods of the present application are described in Table 4.
[0107] In some embodiments, the sgRNA is modified. In some embodiments, the sgRNA comprises the modification pattern shown below in SEQ ID NO: 261, wherein N is any natural or non-natural nucleotide, and wherein all N comprises a guide sequence as described herein, and the modified sgRNA comprises the following sequence: mN*mN*mN*NNNNNNNNNNNNNNNGUUUUAGAmGmCmUmAmGmAmAmAmUmAmGmCAAGUUAAAAUAAGGCUAGUCCGUUAUCAmAmCmUmUmGmAmAmAmAmAmGmUmGmGmCmAmCmCmGmAmGmUmCmGmUmGmCmUmGmUmGmCm U*mU*mU*mU (SEQ ID NO: 261), wherein "N" can be any natural or non-natural nucleotide; * = PS bond; 'm' = 2'-O-Me nucleotide. Despite replacing N with a guide nucleotide, the modification remains in SEQ ID NO: 261. That is, although the guide nucleotide has "N" replaced, the first three nucleotides are 2'OMe modified, and there are phosphorothioate bonds between the first and second nucleotides, between the second and third nucleotides, and between the third and fourth nucleotides.
[0108] In some embodiments, the gRNA sequence has a modification pattern described in WO2016164356 and WO2016089433, each of which is incorporated herein in its entirety.
[0109] In some embodiments, the gRNA comprises a guide sequence that guides the RNA-guided DNA binder (which can be a nuclease (e.g., a Cas nuclease, such as Cas9)) to a target DNA sequence in TTR. The gRNA includes a crRNA having a guide sequence as shown in Table 3. The gRNA includes a guide sequence of at least 15, 16, 17, 18, 19, or 20 consecutive nucleotides of any one of the guide sequences of SEQ ID NOs: 1-47 as shown in Table 3, or a guide sequence of at least 18, 19, or 20 consecutive nucleotides of any one of the guide sequences of SEQ ID NOs: 48-81 as shown in Table 3, or a guide sequence of at least 18, 19, or 20 consecutive nucleotides of any one of the guide sequences of SEQ ID NOs: 275-307 as shown in Table 3. In some embodiments, the gRNA comprises a guide sequence having a sequence having about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to at least 16, 17, 18, 19, or 20 consecutive nucleotides of any one of the guide sequences of SEQ ID NOs: 1-47 shown in Table 3, or a sequence having about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to at least 18, 19, or 20 consecutive nucleotides of any one of the guide sequences of SEQ ID NOs: 48-81, or a sequence having about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to at least 18, 19, or 20 consecutive nucleotides of any one of the guide sequences of SEQ ID NOs: At least 18, 19 or 20 consecutive nucleotides of any one of the guide sequences of NO: 275-307 have a sequence of about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity. The gRNA may also include tracr RNA (trRNA). In each composition and method embodiment described herein, crRNA and trRNA can be associated into a single RNA (sgRNA), or can be located on a separate RNA (dgRNA). In the case of sgRNA, crRNA and trRNA components can be covalently linked, for example, covalently linked via a phosphodiester bond or other covalent bonds.
[0110] In each of the compositions, uses, and method embodiments described herein, the guide RNA may comprise two RNA molecules, as a "dual guide RNA" or "dgRNA". The dgRNA comprises a first RNA molecule comprising a crRNA having a guide sequence, such as shown in Table 3, and a second RNA molecule having a trRNA. The first and second RNA molecules may not be covalently linked, but may form an RNA duplex by base pairing between a portion of the crRNA and the trRNA.
[0111] In each composition, use and method embodiment described herein, the guide RNA may comprise a single RNA molecule as a "single guide RNA" or "sgRNA". The sgRNA may comprise a crRNA (or a portion thereof) having a guide sequence as shown in Table 3, which is covalently linked to the trRNA. The sgRNA may comprise at least 15, 16, 17, 18, 19 or 20 consecutive nucleotides of any one of the guide sequences of SEQ ID NO: 1-47 shown in Table 3, or at least 18, 19 or 20 consecutive nucleotides of any one of the guide sequences of SEQ ID NO: 48-81 shown in Table 3, or at least 18, 19 or 20 consecutive nucleotides of any one of the guide sequences of SEQ ID NO: 275-307 shown in Table 3. In some embodiments, the crRNA and trRNA are covalently linked via a linker. In some embodiments, the sgRNA forms a stem-loop structure via base pairing between a portion of the crRNA and the trRNA. In some embodiments, the crRNA and the trRNA are covalently linked by one or more bonds other than phosphodiester bonds.
[0112] In some embodiments, trRNA may include all or part of a trRNA sequence derived from a naturally occurring CRISPR / Cas system. In some embodiments, trRNA includes truncated or modified wild-type trRNA. The length of trRNA depends on the CRISPR / Cas system used. In some embodiments, trRNA includes or is composed of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100 or more than 100 nucleotides. In some embodiments, trRNA may include some secondary structures, such as, for example, one or more hairpins or stem-loop structures, or one or more protruding structures. In some embodiments, the composition comprises a gRNA comprising a guide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to at least 16, 17, 18, 19, or 20 consecutive nucleotides of any one of the guide sequences of SEQ ID NOs: 1-47 shown in Table 3, or a sequence having about 75%, 80%, 85%, 90%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to at least 18, 19, or 20 consecutive nucleotides of any one of the guide sequences of SEQ ID NOs: 48-81, or a sequence having about 75%, 80%, 85%, 90%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to at least 18, 19, or 20 consecutive nucleotides of any one of the guide sequences of SEQ ID NOs: At least 18, 19 or 20 consecutive nucleotides of any of the guide sequences of NOs:275-307 have a sequence that is about 75%, 80%, 85%, 90%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical.
[0113] In some embodiments, the composition comprises a guide RNA having a guide sequence selected from SEQ ID NO: 1-81 or SEQ ID NO: 275-307. The guide RNA having a guide sequence selected from SEQ ID NO: 1-81 or SEQ ID NO: 275-307 can be a chemically modified sgRNA, such as a terminally modified RNA. The guide RNA having a guide sequence selected from SEQ ID NO: 1-81 or SEQ ID NO: 275-307 can be a dgRNA, such as a chemically modified dgRNA.
[0114] In other embodiments, the composition comprises at least one (e.g., at least two) gRNAs having a guide sequence selected from any two or more of the guide sequences of SEQ ID NOs: 1-81 or SEQ ID NOs: 275-307. In some embodiments, the composition comprises at least two gRNAs, each of which comprises a guide sequence that is at least 90%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of the nucleic acids of SEQ ID NOs: 1-81 or SEQ ID NOs: 275-307.
[0115] In some embodiments, the gRNA is an sgRNA having any one of SEQ ID NO: 171-251 or SEQ ID NO: 341-373. In some embodiments, the gRNA is an sgRNA having any one of SEQ ID NO: 171-251 or SEQ ID NO: 341-373, but without the modifications described in the present application (ie, unmodified SEQ ID NO: 171-251 or SEQ ID NO: 341-373). In some embodiments, the gRNA is an sgRNA having any one of SEQ ID NO: 171-251 or SEQ ID NO: 341-373, but with at least one chemical modification. In some embodiments, the chemically modified SEQ ID NO: 171-251 or SEQ ID NO: 341-373 has a 5' and / or 3' end modification. In some embodiments, the gRNA is a sgRNA having any one of SEQ ID NOs: 171-251 or SEQ ID NOs: 341-373, but having a modification pattern shown in SEQ ID NO: 261.
[0116] The guide RNA provided herein can be used to identify (e.g., hybridize) a target sequence in a TTR gene. For example, a TTR target sequence can be recognized and cleaved by a Cas nuclease provided with a guide RNA. Thus, an RNA-guided DNA binder (such as a Cas nuclease) can be guided to a target sequence of a TTR gene by a guide RNA, wherein the guide sequence of the guide RNA hybridizes with the target sequence, and the RNA-guided DNA binder (such as a Cas nuclease) cleaves the target sequence.
[0117] In some embodiments, the selection of one or more guide RNAs is determined based on a target sequence within a TTR gene. For example, the one or more guide RNAs are based on a target sequence within any of exons 1-4 or the 5'RR region of a TTR gene.
[0118] Without being bound by any particular theory, mutations in certain regions of the gene (e.g., frameshift mutations due to insertions / deletions that occur due to nuclease-mediated DSBs) may be less tolerated than mutations in other regions of the gene, and therefore, the location of the DSB is an important factor in the amount or type of protein knockdown that may result. In some embodiments, an RNA-guided DNA binder is guided to a specific location in the TTR gene using a gRNA that is complementary or has complementarity to a target sequence within TTR. In some embodiments, the gRNA is designed to have a guide sequence that is complementary or has complementarity to a target sequence in exon 1, exon 2, exon 3, or exon 4 of TTR. In some embodiments, frameshift or nonsense mutations are induced in the TTR gene in about 10%, about 15%, about 20%, about 25%, about 30% to about 35% of cells.
[0119] B. gRNA modification
[0120] In some embodiments, the gRNA is chemically modified. A gRNA having one or more modified nucleosides or nucleotides is referred to as a "modified" gRNA or a "chemically modified" gRNA to describe the presence of one or more non-natural and / or naturally occurring components or configurations that are used to replace or supplement typical A, G, C, and U residues (including T). In some embodiments, a modified gRNA is synthesized with atypical nucleosides or nucleotides, referred to herein as "modified". Modified nucleosides and nucleotides may include one or more of the following: (i) alteration (e.g., replacement) of one or both non-linked phosphate oxygens and / or one or more linked phosphate oxygens in the phosphodiester backbone linkage (exemplary backbone modifications); (ii) alteration (e.g., replacement) of the composition of the ribose sugar (e.g., the 2' hydroxyl group on the ribose sugar) (exemplary sugar modifications); (iii) global replacement of the phosphate moiety with a "dephosphorylated" linker (exemplary backbone modification); (iv) modification or replacement of naturally occurring nucleobases, including modification or replacement with atypical nucleobases (exemplary base modifications); (v) replacement or modification of the ribose-phosphate backbone (exemplary backbone modification); (vi) modification of the 3' or 5' end of the oligonucleotide, such as removal, modification or replacement of the terminal phosphate group or a conjugated moiety, cap or linker (such 3' or 5' cap modifications may include sugar and / or backbone modifications); and (vii) modification or replacement of the sugar (exemplary sugar modifications).
[0121] Chemical modifications such as those described above can be combined to provide modified gRNAs having nucleosides and nucleotides (collectively referred to as "residues") that may have two, three, four or more modifications. For example, the modified residues may have modified sugars and modified nucleobases. In some embodiments, each base of the gRNA is modified, for example, all bases have modified phosphate groups, such as thiophosphate groups. In certain embodiments, all or substantially all phosphate groups of the gRNA molecule are replaced by thiophosphate groups. In some embodiments, the modified gRNA comprises at least one modified residue at or near the 5' end of the RNA. In some embodiments, the modified gRNA comprises at least one modified residue at or near the 3' end of the RNA.
[0122] In some embodiments, the gRNA comprises one, two, three or more modified residues. In some embodiments, at least 5% (e.g., at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100%) of the position in the modified gRNA is a modified nucleoside or nucleotide.
[0123] Unmodified nucleic acids may be susceptible to degradation by, for example, nucleases in cells or serum. For example, nucleases can hydrolyze nucleic acid phosphodiester bonds. Therefore, in one aspect, the gRNA described herein may include one or more modified nucleosides or nucleotides, for example, to introduce stability to intracellular or serum nucleases. In some embodiments, the modified gRNA molecules described herein may show reduced innate immune responses when introduced into cell populations in vivo and in vitro. The term "innate immune response" includes cellular responses to exogenous nucleic acids (including single-stranded nucleic acids), which involve inducing cytokine expression and release (particularly interferon) and cell death.
[0124] In some embodiments of backbone modification, the phosphate group of the modified residue can be modified by replacing one or more oxygens with different substituents. In addition, the modified residue (e.g., the modified residue present in the modified nucleic acid) can include the comprehensive replacement of the unmodified phosphate moiety with the modified phosphate group described herein. In some embodiments, the backbone modification of the phosphate backbone can include the change that causes an uncharged joint or a charged joint with an asymmetric charge distribution.
[0125] The example of the phosphate group of modification comprises phosphorothioate, phosphoroselenate, boranophosphoric acid, boranophosphate, hydrogen phosphonate, phosphoramidate, alkyl or aryl phosphonate and phosphotriester.The phosphorus atom in the unmodified phosphate group is achiral.But, replacing one of the non-bridging oxygen with one of the above-mentioned atoms or atomic groups can make the phosphorus atom have chirality.The stereoisomerism phosphorus atom can have " R " configuration (here Rp) or " S " configuration (here Sp).The main chain can also be modified by replacing the bridging oxygen (i.e. the oxygen connecting phosphate and nucleosides) with nitrogen (bridging phosphoramidate), sulfur (bridging phosphorothioate) and carbon (bridging methylene phosphonate).Replacement can occur at any connection oxygen place or two connection oxygen places.
[0126] In some main chain modifications, the phosphate group can be replaced by a phosphorus-free linker. In some embodiments, the charged phosphate group can be replaced by a neutral moiety. Examples of substitutable phosphate groups include, but are not limited to, for example, methylphosphonates, hydroxyamino groups, siloxanes, carbonates, carboxymethyl groups, carbamates, amides, thioethers, ethylene oxide joints, sulfonates, sulfonamides, thioformal, methylal, oximes, methyleneimino groups, methylenemethylimino groups, methylenehydrazine groups, methylenedimethylhydrazine groups, and methyleneoxymethylimino groups.
[0127] Can also construct the framework that can simulate nucleic acid, wherein phosphate joint and ribose are replaced by nuclease resistant nucleoside or nucleotide substitute.Such modification can comprise main chain and sugar modification.In some embodiments, core base can be connected by alternative main chain.Example can include but not limited to, morpholino, cyclobutyl, pyrrolidine and peptide nucleic acid (PNA) nucleoside substitute.
[0128] Modified nucleosides and modified nucleotides can include one or more modifications to the sugar group, i.e., sugar modifications. For example, the 2' hydroxyl (OH) can be modified, for example, replaced with a number of different "oxygen" or "deoxy" substituents. In some embodiments, the modification of the 2' hydroxyl can enhance the stability of the nucleic acid because the hydroxyl can no longer be deprotonated to form a 2'-alkoxide ion.
[0129] Examples of 2'hydroxyl modifications can include alkoxy or aryloxy (OR, where "R" can be, for example, an alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or sugar); polyethylene glycol (PEG), 0(CH2CH20)nCH2CH2OR, where R can be, for example, H or an optionally substituted alkyl, and n can be an integer from 0 to 20 (e.g., 0 to 4, 0 to 8, 0 to 10, 0 to 16, 1 to 4, 1 to 8, 1 to 10, 1 to 16, 1 to 20, 2 to 4, 2 to 8, 2 to 10, 2 to 16, 2 to 20, 4 to 8, 4 to 10, 4 to 16, and 4 to 20). In some embodiments, the 2'hydroxyl modification can be 2'-O-Me. In some embodiments, the 2'hydroxyl modification can be a 2'-fluoro modification, which replaces the 2'hydroxyl with fluoride. In some embodiments, the 2' hydroxyl modification may include a "locked" nucleic acid (LNA), wherein the 2' hydroxyl may be connected to the 4' carbon of the same ribose by, for example, a C1-6 alkylene or C1-6 heteroalkylene bridge, wherein exemplary bridges may include methylene, propylene, ether or amino bridges; O-amino (wherein the amino group may be, for example, NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino or diheteroarylamino, ethylenediamine or polyamino) and aminoalkoxy, O(CH2)n-amino (wherein the amino group may be, for example, NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino or diheteroarylamino, ethylenediamine or polyamino). In some embodiments, the 2' hydroxyl modification may include an "unlocked" nucleic acid (UNA), wherein the ribose ring lacks a C2'-C3' bond. In some embodiments, the 2' hydroxyl modification may include a methoxyethyl (MOE) (OCH2CH2OCH3, for example, a PEG derivative).
[0130] "Deoxy" 2' modifications can include hydrogen (i.e., deoxyribose, such as in the overhang of a portion of a dsRNA); halogen (e.g., bromine, chloride, fluorine, or iodine); amino (wherein the amino group can be, for example, NEE; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, diheteroarylamino, or an amino acid); NH(CH2CH2NH)nCH2CH2-amino (wherein the amino group can be, for example, as described herein), -NHC(0)R (wherein R can be, for example, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or a sugar), cyano; thiol; alkylthioalkyl; thioalkoxy; and alkyl, cycloalkyl, aryl, alkenyl, and alkynyl groups, which can be optionally substituted with, for example, amino groups as described herein.
[0131] Sugar modification can include sugar groups, and this sugar group can also include one or more carbons with stereochemical configuration opposite to the corresponding carbon in ribose.Therefore, the nucleic acid of modification can include nucleotides containing, for example, arabinose as sugar.The nucleic acid of modification can also include abasic sugars.These abasic sugars can also be further modified at one or more composition sugar atoms.The nucleic acid of modification can also include one or more L forms of sugar, for example L-nucleosides.
[0132] Modified nucleosides and modified nucleotides that can be incorporated into modified nucleic acids as described herein may include modified bases, also referred to as core bases. Examples of core bases include, but are not limited to, adenine (A), guanine (G), cytosine (C), thymidine (T) and uracil (U). These core bases may be modified or completely replaced to provide modified residues that can be incorporated into modified nucleic acids. The core bases of nucleotides may be independently selected from purine, pyrimidine, purine analogs or pyrimidine analogs. In some embodiments, core bases may include, for example, naturally occurring and synthetic derivatives of bases.
[0133] In embodiments employing dual guide RNAs, each of the crRNA and tracr RNA may include modifications. Such modifications may be located at one or both ends of the crRNA and / or tracr RNA. In embodiments with sgRNA, one or more residues at one or both ends of the sgRNA may be chemically modified, or the entire sgRNA may be chemically modified. Certain embodiments include 5' end modifications. Certain embodiments include 3' end modifications. In certain embodiments, one or more or all nucleotides in the single-stranded overhang of the guide RNA molecule are deoxynucleotides.
[0134] In some embodiments, the gRNA may have one or more modifications. In some embodiments, the modification includes 2'-O-methyl (2'-O-Me) modified nucleotides. In some embodiments, the modification includes phosphorothioate (PS) bonds between nucleotides.
[0135] The terms "mA," "mC," "mU," or "mG" may be used to denote a nucleotide that has been modified with 2'-O-Me.
[0136] In some embodiments, the guide RNA includes an sgRNA having a guide sequence selected from SEQ ID NOs: 1-81 or SEQ ID NOs: 275-307 and a nucleotide of SEQ ID NO: 258, wherein the nucleotide of SEQ ID NO: 258 is located at the 3' end of the guide sequence, and wherein the guide sequence can be modified as shown in SEQ ID NO: 261.
[0137] Further examples of gRNA modifications are shown, for example, in WO2020198697, WO2016164356 and WO2016089433, which are incorporated herein by reference in their entirety.
[0138] C. PAM sequence
[0139] PAM, also known as the protospacer adjacent motif, is a short specific sequence complementary to a portion of the gRNA, located after the target DNA sequence necessary for Cas nuclease cleavage. The PAM is located about 2-8 nucleotides downstream of the DNA sequence targeted by the guide RNA, and Cas cuts 3-4 nucleotides upstream of it. The PAM sequence is illustrated in Table 1-2 below. The PAM in this application can be any of the sequences in Table 1-2 or any other sequence known in the art.
[0140] Table 1: PAMs of synthetic spCas9 variants
[0141]
[0142] N is A, G, C or T.
[0143] Table 2: PAMs of different Cas9 species
[0144] Cas9 species PAM Sequence Streptococcus pyogenes (Sp) NGG (SEQ ID NO: 262) Staphylococcus aureus (Sa) NGRRN (SEQ ID NO: 267) Neisseria meningitidis (Nm or Nme) NNNNGATT (SEQ ID NO: 268) Campylobacter jejuni (Cj) NNNNRYAC (SEQ ID NO: 269) Streptococcus thermophilus (St) NNAGAAW (SEQ ID NO: 270) Treponema denticola (Td) NAAAAC (SEQ ID NO: 271)
[0145] N is A, G, C or T.
[0146] D. RNA-guided DNA binders
[0147] Any nucleic acid with an open reading frame encoding an RNA-guided DNA binder (e.g., Cas9 nuclease, such as Streptococcus pyogenes Cas9) can be combined with any gRNA disclosed herein in a composition or method. In some embodiments, the nucleic acid with an open reading frame encoding an RNA-guided DNA binder is mRNA. In some embodiments, the RNA-guided DNA binder is administered in its amino acid form (i.e., as a protein). In some embodiments, the nucleic acid encoding the RNA-guided DNA binder is part of a vector described herein. The nucleic acid encoding the RNA-guided DNA binder may have any of the features described in WO2020198697, which is incorporated herein by reference in its entirety.
[0148] In some embodiments, the RNA-guided DNA binder for the compositions and methods described herein is a Class 2 Cas nuclease. In some embodiments, the RNA-guided DNA binder has double-stranded endonuclease activity. In some embodiments, the RNA-guided DNA binder comprises a Cas nuclease, such as a Class 2 Cas nuclease (which may be, for example, a II, V, or VI type Cas nuclease). Class 2 Cas nucleases include, for example, Cas9, Cpfl, C2cl, C2c2, and C2c3 proteins and modifications thereof.
[0149] Examples of Cas9 nucleases include those of the type II CRISPR systems of Streptococcus pyogenes, Staphylococcus aureus, and other prokaryotes (see, e.g., the list in the next paragraph) and modified (e.g., engineered or mutated) versions thereof. See, e.g., US2016 / 0312198A1; US2016 / 0312199A1. Other examples of Cas nucleases include the Csm or Cmr complexes of the type III CRISPR system, or its Cas10, Csml, or Cmr2 subunits; and the Cascade complexes of the type I CRISPR system, or its Cas3 subunits. In some embodiments, the Cas nuclease may be from a type IIA, type IIB, or type IIC system. For discussion of various CRISPR systems and Cas nucleases, see, e.g., Makarova et al., Nat. Rev. Microbiol. 9:467-477 (2011); Makarova et al., Nat. Rev. Microbiol, 13:722-36 (2015); Shmakov et al., Molecular Cell, 60:385-397 (2015). In some embodiments, the RNA-guided DNA binder is a Cas nickase, such as a Cas9 nickase. In some embodiments, the RNA-guided DNA binder is a Streptococcus pyogenes Cas9 nuclease.
[0150] Non-limiting exemplary species from which RNA-guided DNA binders (e.g., Cas nucleases) can be derived include, but are not limited to, Streptococcus pyogenes, Streptococcus thermophilus, Streptococcus sp.), Staphylococcus aureus, Listeria innocua, Lactobacillus gasseri, Francisella novicida, Wolinella succinogenes, Sutterella wadsworthensis, Gammaproteobacterium, Neisseria meningitidis, Campylobacter Jejuni, Pasteurella multocida, Fibrobacter succinogene, Rhodospirillum rubrum, Nocardiopsis dassonvillei, Streptomyces pristinaespiralis), Streptomyces viridochromogenes, Streptomyces viridochromogenes, Streptosporangium roseum, Streptosporangium roseum, Alicyclobacillus acidocaldarius, Bacillus pseudomycoides, Bacillus selenitireducens, Exiguobacterium sibiricum, Lactobacillus delbrueckii, Lactobacillus salivarius, Lactobacillus buchneri, Treponema denticola, Microscilla marina, Burkholderiales bacterium, Polaromonas naphthalene-degrading naphthalenivorans), Polaromonas sp., Crocosphaera watsonii, Cyanothece sp.), Microcystis aeruginosa, Synechococcus sp., Acetohalobium arabaticum, Ammonifex degensii, Caldicelulosiruptor becscii, Candidatus Desulforudis, Clostridium botulinum, Clostridium difficile, Finegoldia magna, Natranaerobius thermophilus, Pelotomaculum thermopropionicum, Acidithiobacillus caldus, Acidithiobacillus ferrooxidans, Allochromatium vinosum, Marinobacter sp.), Nitrosococcus halophilus, Nitrosococcus watsoni, Pseudoalteromonas haloplanktis, Ktedonobacter racemifer, Methanohalobium evestigatum, Anabaena variabilis, Nodularia spumigena, Nostoc sp., Arthrospira maxima, Arthrospira platensis, Arthrospira sp., Lyngbya sp., Microcoleus chthonoplastes, Oscillatoria sp.), Petrotoga mobilis, Thermosipho africanus, Streptococcus pasteurianus, Neisseria cinerea, Campylobacter Zari, Parvibaculum lavamentivorans, Corynebacterium diphtheria, Acidaminococcus sp., Lachnospiraceae bacteria ND2006 and Acaryochloris marina.
[0151] In some embodiments, the Cas nuclease is a Cas9 nuclease from Streptococcus pyogenes. In some embodiments, the Cas nuclease is a Cas9 nuclease from Streptococcus thermophilus. In some embodiments, the Cas nuclease is a Cas9 nuclease from Neisseria meningitidis. In some embodiments, the Cas nuclease is a Cas9 nuclease from Staphylococcus aureus. In some embodiments, the Cas nuclease is a Cpf1 nuclease from Francisella novicida. In some embodiments, the Cas nuclease is a Cpf1 nuclease from Acidococcus. In some embodiments, the Cas nuclease is a Cpf1 nuclease from the genus Acidococcus. In some embodiments, the Cas nuclease is a Cpf1 nuclease from the bacterium ND2006 of the family Lachnospiraceae. In some embodiments, the Cas nuclease is from Francisella tularensis, Lachnospiraceae, Butyrivibrioproteoclasticus, Peregrinibacteria bacterium, Parcubacteria bacterium, Smithella, Acidaminococcus, Candidatus Methanoplasma termitum, Eubacterium eligens, Moraxella bovoculi, Leptospira inadai, Porphyromonas crevioricanis, Prevotella disiens, or Porphyromonas macaques. macacae). In some embodiments, the Cas nuclease is a Cpf1 nuclease from Acidaminococcus or Lachnospiraceae.
[0152] Wild-type Cas9 has two nuclease domains: RuvC and HNH. The RuvC domain cleaves the non-target DNA strand, while the HNH domain cleaves the DNA target strand. In some embodiments, the Cas9 nuclease comprises more than one RuvC domain and / or more than one HNH domain. In some embodiments, the Cas9 nuclease is a wild-type Cas9. In some embodiments, Cas9 is capable of inducing double-strand breaks in the target DNA. In certain embodiments, the Cas nuclease can cleave one or both strands of dsDNA. In some embodiments, the Cas nuclease can cleave single-stranded DNA. In some embodiments, the Cas nuclease may not have DNA nickase activity. An exemplary Cas9 amino acid sequence is provided as SEQ ID NO: 272.
[0153]
[0154] An exemplary Cas9 mRNA ORF sequence (including start and stop codons) is provided as SEQ ID NO:273.
[0155]
[0156] An exemplary Cas9 mRNA coding sequence suitable for incorporation into a fusion protein is provided as SEQ ID NO:274.
[0157]
[0158] In some embodiments, a chimeric Cas nuclease is used in which a domain or region of a protein is replaced by a portion of a different protein. In some embodiments, the Cas nuclease domain can be replaced by a domain from a different nuclease (such as Fok 1). In some embodiments, the Cas nuclease can be a modified nuclease.
[0159] In other embodiments, the Cas nuclease may be from a type I CRISPR / Cas system. In some embodiments, the Cas nuclease may be a component of the Cascade complex of a type I CRISPR / Cas system. In some embodiments, the Cas nuclease may be a Cas3 protein. In some embodiments, the Cas nuclease may be from a type III CRISPR / Cas system. In some embodiments, the Cas nuclease may have RNA cleavage activity.
[0160] In some embodiments, the Cas nuclease is fused to an exonuclease, for example, to inhibit repeated cleavage by promoting end processing and incomplete reconnection, thereby reducing chromosomal translocation. In some embodiments, the Cas nuclease is fused to TREX1, TREX2 or MRE11. In some embodiments, the exonuclease is truncated. In some embodiments, the Cas nuclease is fused to an exonuclease or a truncated exonuclease at the C-terminus using a GGGGS linker. Cas exonuclease-endonuclease fusions are described in, for example, Yin J et al. Cas exonuclease-endonuclease eliminates chromosomal translocations during genome editing. Nat Commun. 2022 Mar 8; 13 (1): 1204. doi: 10.1038 / s41467-022-28900-w. PMID: 35260581; PMCID: PMC8904484., which is incorporated herein by reference in its entirety.
[0161] E. Determination of gRNA efficacy
[0162] In some embodiments, the efficacy of the gRNA is determined when delivered with other components (e.g., nucleic acids encoding RNA-guided DNA binders, such as any described herein). In some embodiments, the efficacy of a combination of a gRNA and a nucleic acid encoding an RNA-guided DNA binder is determined.
[0163] As described herein, the use of RNA-guided DNA nucleases and guide RNAs disclosed herein can cause DNA double-strand breaks, which can result in errors in the form of insertion / deletion (indel) mutations when the cell machinery repairs them. Many mutations caused by insertion / deletion will change the reading frame or introduce premature stop codons, thus producing non-functional proteins.
[0164] In some embodiments, the efficacy of a specific gRNA or combination is determined based on an in vitro model. In some embodiments, the in vitro model is a HEK293 cell. In some embodiments, the in vitro model is a HUH7 human liver cancer cell. In some embodiments, the in vitro model is a HepG2 cell. In some embodiments, the in vitro model is a primary human hepatocyte. In some embodiments, the in vitro model is a primary rodent hepatocyte. In some embodiments, the in vitro model is a primary cynomolgus monkey hepatocyte. With regard to the use of primary human hepatocytes, commercially available primary human hepatocytes can be used to provide greater consistency between experiments. In some embodiments, the number of off-target sites deleted or inserted in an in vitro model (e.g., in primary human hepatocytes) is determined, for example, by analyzing the genomic DNA of primary human hepatocytes transfected with Cas9mRNA and guide RNA in vitro. In some embodiments, this determination includes analyzing the genomic DNA of primary human hepatocytes transfected with Cas9 mRNA and guide RNA in vitro. Such exemplary procedures for determination are provided in the following working examples.
[0165] In some embodiments, the efficacy of a specific gRNA or combination is determined in multiple in vitro cell models to perform a gRNA selection process. In some embodiments, cell line comparisons are performed on the data for the selected gRNA. In some embodiments, cross-screening is performed in multiple cell models.
[0166] In some embodiments, the efficacy of a particular gRNA or combination is determined based on an in vivo model. In some embodiments, the in vivo model is a rodent model. In some embodiments, the rodent model is a mouse that expresses a human TTR gene, which may be a mutated human TTR gene. In some embodiments, the in vivo model is a non-human primate, such as a cynomolgus monkey.
[0167] In some embodiments, the efficacy of the guide RNA or combination is measured by the percentage of editing of TTR. In some embodiments, the percentage of editing of TTR is compared to the percentage of editing required to achieve TTR protein knockdown, for example, in cell culture medium in the case of an in vitro model or in serum or tissue in the case of an in vivo model. In some embodiments, the percentage of editing is 30% to 99% of the cell population. In some embodiments, the percentage of editing is 30% to 35%, 35% to 40%, 40% to 45%, 45% to 50%, 50% to 55%, 55% to 60%, 60% to 65%, 65% to 70%, 70% to 75%, 75% to 80%, 80% to 85%, 85% to 90%, 90% to 95%, or 95% to 99% of the cell population. In some embodiments, the editing percentage is 30%-95%, 40%-90% or 50%-85%, 30%-60%, 40%-80%, 50%-75%, 60%-90%.
[0168] In some embodiments, the efficacy of a guide RNA or combination is measured by the number and / or frequency of insertions / deletions at off-target sequences within the genome of a target cell type. In some embodiments, effective guide RNAs and combinations are provided, which produce insertions / deletions at off-target sites at very low frequencies (e.g., <5%) in cell populations and / or relative to the frequency of insertions / deletions at the target site. Therefore, the application provides guide RNAs that do not show off-target insertions / deletions in target cell types (e.g., hepatocytes), or produce off-target insertions / deletions in cell populations and / or relative to the frequency of insertions / deletions at the target site. In some embodiments, the application provides guide RNAs and combinations that do not show any off-target insertions / deletions in target cell types (e.g., hepatocytes).
[0169] In some embodiments, guide RNAs and combinations are provided that produce insertions / deletions at less than 5 off-target sites, e.g., as assessed by one or more methods described herein. In some embodiments, guide RNAs and combinations that produce insertions / deletions at less than or equal to 4, 3, 2, or 1 off-target sites are provided, e.g., as assessed by one or more methods described herein. In some embodiments, the off-target sites do not occur in protein coding regions in the genome of target cells (e.g., hepatocytes).
[0170] In some embodiments, gene editing events, such as the formation of insertion / deletion ("indel") mutations and homology-directed repair (HDR) events in the target DNA, are detected by linear amplification of labeled primers and separation of labeled amplification products (hereinafter referred to as "LAM-PCR" or "linear amplification (LA)" method), as described in WO2018 / 067447 or Schmidt et al., Nature Methods 4: 1051-1057 (2007).
[0171] In some embodiments, gene editing events are detected, such as forming insertion / deletion ("indel") mutations and homology-directed repair (HDR) events in the target DNA, and also include sequencing the linear amplification product or further amplification product. Sequencing may include any method known to those skilled in the art, including next-generation sequencing, and cloning the linear amplification product or further amplification product into a plasmid and sequencing a portion of the plasmid or plasmid. Exemplary next-generation sequencing methods are discussed in, for example, Shendure et al., Nature 26: 1135-1145 (2008). In other aspects, gene editing events are detected, such as forming insertion / deletion ("indel") mutations and homology-directed repair (HDR) events in the target DNA, and also include performing digital PCR (dPCR) or droplet digital PCR (ddPCR) on the linear amplification product or further amplification product, or contacting the linear amplification product or further amplification product with a nucleic acid probe designed to identify DNA with homology-directed repair (HDR) template sequences and detecting probes that have been combined with the linear amplification product or further amplification product. In some embodiments, the method further comprises determining the position of the HDR template in the target DNA.
[0172] In certain embodiments, the method further comprises determining a sequence of an insertion site in the target DNA, wherein the insertion site is the location at which the HDR template is inserted into the target DNA, and wherein the insertion site may include some target DNA sequence and some HDR template sequence.
[0173] In some embodiments, the efficacy of the guide RNA or combination is measured by secretion of TTR. In some embodiments, secretion of TTR is measured using an enzyme-linked immunosorbent assay (ELISA) assay performed on cell culture medium or serum. In some embodiments, secretion of TTR is measured in the same in vitro or in vivo system or model used to measure editing. In some embodiments, secretion of TTR is measured in primary human hepatocytes. In some embodiments, secretion of TTR is measured in HUH7 cells. In some embodiments, secretion of TTR is measured in HepG2 cells. In some embodiments, secretion of TTR is measured in HEK cells.
[0174] ELISA assays are well known to those skilled in the art and can be designed to measure serum TTR levels. In an exemplary embodiment, blood is collected and serum is separated. Total TTR serum levels can be measured using a mouse prealbumin (transthyretin) ELISA kit (Aviva Systems Biology) or a similar kit for measuring human TTR. If no kit is available, an ELISA can be developed using a plate pre-coated with a capture antibody specific for the TTR being measured. The plate is then incubated at room temperature for a period of time and then washed. An enzyme-anti-TTR antibody conjugate is added and incubated. Unbound antibody conjugate is removed and the plate is washed before adding a chromogenic substrate solution that reacts with the enzyme. The plate is read on an appropriate plate reader to obtain an absorbance specific for the enzyme and substrate used.
[0175] In some embodiments, the efficacy of gRNA or combination is measured by the amount of TTR in cells (including cells from tissues). In some embodiments, the amount of TTR in cells is measured using Western blotting. In some embodiments, the cells used are HUH7 cells. In some embodiments, the cells used are primary human hepatocytes. In some embodiments, the cells used are primary cells obtained from animals. In some embodiments, the amount of TTR is compared with the amount of glyceraldehyde 3-phosphate dehydrogenase GAPDH (housekeeping gene) to control changes in cell number.
[0176] In some embodiments, the amount of TTR is reduced by 30% to 35%, 35% to 40%, 40% to 45%, 45% to 50%, 50% to 55%, 55% to 60%, 60% to 65%, 65% to 70%, 70% to 75%, 75% to 80%, 80% to 85%, 85% to 90%, 90% to 95%, or 95% to 99% compared to TTR detected in cells in the subject prior to administration of the composition. In some embodiments, the amount of TTR is reduced by 30%-95%, 40%-90%, or 50%-85%, 30%-60%, 40%-80%, 50%-75%, or 60%-90% compared to TTR detected in cells in the subject prior to administration of the composition.
[0177] In some embodiments, the degree or amount of amyloidosis is measured by methods known in the art. For example, blood tests, urine tests, and / or biopsies can be used to measure amyloidosis in a subject. A bone marrow examination or other small biopsy sample of a tissue or organ can positively confirm the diagnosis of amyloidosis. In some embodiments, cardiac amyloidosis can be measured by cardiac biopsy, technetium pyrophosphate scanning, or radionuclide imaging, as described in Hotta M et al., Radiography 2020; 40: 2029–2041.
[0178] In some embodiments, the amyloidosis is reduced by 30% to 35%, 35% to 40%, 40% to 45%, 45% to 50%, 50% to 55%, 55% to 60%, 60% to 65%, 65% to 70%, 70% to 75%, 75% to 80%, 80% to 85%, 85% to 90%, 90% to 95%, or 95% to 99% compared to the amyloidosis detected in the tissue of the subject before administration of the composition. In some embodiments, the amyloidosis is reduced by 30%-95%, 40%-90%, or 50%-85%, 30%-60%, 40%-80%, 50%-75%, or 60%-90% compared to the amyloidosis detected in the tissue of the subject before administration of the composition.
[0179] F. Treatment Methods
[0180] In some embodiments, the present application provides a method for treating ATTR, comprising administering a composition comprising a guide RNA having any one or more guide sequences of SEQ ID NO: 1-81 or SEQ ID NO: 275-307, or any one or more sgRNAs of SEQ ID NO: 171-251 or SEQ ID NO: 341-373, or any one or more crRNAs of SEQ ID NO: 86-166 or SEQ ID NO: 308-340. In some embodiments, a gRNA having any one or more guide sequences of SEQ ID NO: 1-81 or SEQ ID NO: 275-307, or any one or more sgRNAs of SEQ ID NO: 171-251 or SEQ ID NO: 341-373 is administered to treat ATTR. The guide RNA is administered together with a nucleic acid or vector encoding an RNA-guided DNA nuclease described herein, such as a Cas nuclease (e.g., Cas9). The RNA-guided DNA nuclease can be Streptococcus pyogenes Cas9. In a specific embodiment, the guide RNA is chemically modified. In some embodiments, the guide RNA and the nucleic acid encoding the RNA-guided DNA nuclease are administered in an LNP described herein, such as an LNP with a CCD lipid (e.g., an amine lipid such as lipid A), a helper lipid (e.g., cholesterol), a stealth lipid (e.g., a PEG lipid such as PEG2k-DMG), and optionally a neutral lipid (e.g., DSPC).
[0181] In some embodiments, the present application provides a method of inducing a double-strand break (DSB) in a TTR gene, comprising administering a composition having a guide RNA described herein (e.g., having any one or more guide sequences of SEQ ID NO: 1-81 or SEQ ID NO: 275-307) or any one or more sgRNAs of SEQ ID NO: 171-251 or SEQ ID NO: 341-373. In some embodiments, a gRNA, such as any one or more guide sequences of SEQ ID NO: 1-81 or SEQ ID NO: 275-307, is administered to recognize and bind to the TTR gene. The guide RNA is administered together with a nucleic acid (e.g., mRNA) or a vector encoding an RNA-guided DNA nuclease described herein, such as a Cas nuclease (e.g., Cas9). The RNA-guided DNA nuclease can be Streptococcus pyogenes Cas9. In specific embodiments, the guide RNA is chemically modified. In some embodiments, the guide RNA and a nucleic acid encoding an RNA-guided DNA nuclease. In some embodiments, a method of inducing a double-strand break (DSB) in a TTR gene is provided, comprising administering a composition comprising a guide RNA (such as a chemically modified guide RNA) comprising any one or more guide sequences of SEQ ID NO: 1-81 or SEQ ID NO: 275-307, or any one or more sgRNAs of SEQ ID NO: 171-251 or SEQ ID NO: 341-373. In some embodiments, any one or more sgRNAs of SEQ ID NO: 171-251 or SEQ ID NO: 341-373 or a gRNA comprising any one or more guide sequences of SEQ ID NO: 1-81 or SEQ ID NO: 275-307 is administered to induce a DSB in a TTR gene. The guide RNA is administered with a nucleic acid or vector encoding an RNA-guided DNA nuclease as described herein, such as a Cas nuclease (e.g., Cas9). The RNA-guided DNA nuclease can be Streptococcus pyogenes Cas9. In a specific embodiment, the guide RNA is chemically modified. In some embodiments, the guide RNA and the nucleic acid encoding the RNA-guided DNA nuclease are administered in an LNP described herein, such as an LNP comprising a CCD lipid (e.g., an amine lipid such as lipid A), a helper lipid (e.g., cholesterol), a stealth lipid (e.g., a PEG lipid such as PEG2k-DMG), and optionally a neutral lipid (e.g., DSPC).
[0182] In some embodiments, a method of modifying a TTR gene is provided, comprising administering a composition comprising a guide RNA described herein (e.g., having any one or more guide sequences of SEQ ID NO: 1-81 or SEQ ID NO: 275-307) or any one or more sgRNAs of SEQ ID NO: 171-251 or SEQ ID NO: 341-373. In some embodiments, a gRNA comprising any one or more guide sequences of SEQ ID NO: 1-81 or SEQ ID NO: 275-307, or any one or more sgRNAs of SEQ ID NO: 171-251 or SEQ ID NO: 341-373 is administered to modify the TTR gene. The guide RNA is administered together with a nucleic acid or vector encoding an RNA-guided DNA nuclease described herein, such as a Cas nuclease (e.g., Cas9). The RNA-guided DNA nuclease can be Streptococcus pyogenes Cas9. In a specific embodiment, the guide RNA is chemically modified. In some embodiments, the guide RNA and the nucleic acid encoding the RNA-guided DNA nuclease are administered in an LNP described herein, such as an LNP comprising a CCD lipid (e.g., an amine lipid such as lipid A), a helper lipid (e.g., cholesterol), a stealth lipid (e.g., a PEG lipid such as PEG2k-DMG), and optionally a neutral lipid (e.g., DSPC).
[0183] In some embodiments, a method of modifying a TTR gene is provided, comprising administering a composition comprising a guide RNA comprising any one or more guide sequences of SEQ ID NO: 1-81 or SEQ ID NO: 275-307 or any one or more sgRNAs of SEQ ID NO: 171-251 or SEQ ID NO: 341-373. In some embodiments, a gRNA comprising any one or more guide sequences of SEQ ID NO: 1-81 or SEQ ID NO: 275-307 or any one or more sgRNAs of SEQ ID NO: 171-251 or SEQ ID NO: 341-373 is administered to modify the TTR gene. The guide RNA is administered together with a nucleic acid or vector encoding an RNA-guided DNA nuclease described herein, such as a Cas nuclease (e.g., Cas9). The RNA-guided DNA nuclease can be Streptococcus pyogenes Cas9. In a specific embodiment, the guide RNA is chemically modified. In some embodiments, the guide RNA and the nucleic acid encoding the RNA-guided DNA nuclease are administered in an LNP described herein, such as an LNP comprising a CCD lipid (e.g., an amine lipid such as lipid A), a helper lipid (e.g., cholesterol), a stealth lipid (e.g., a PEG lipid such as PEG2k-DMG), and optionally a neutral lipid (e.g., DSPC).
[0184] In some embodiments, a method of treating ATTR is provided, comprising administering a composition comprising a guide RNA described herein (e.g., having any one or more guide sequences of SEQ ID NO: 1-81 or SEQ ID NO: 275-307) or any one or more sgRNAs of SEQ ID NO: 171-251 or SEQ ID NO: 341-373. In some embodiments, a gRNA comprising any one or more guide sequences of SEQ ID NO: 1-81 or SEQ ID NO: 275-307, or any one or more sgRNAs of SEQ ID NO: 171-251 or SEQ ID NO: 341-373 is administered to treat ATTR. The guide RNA is administered with a nucleic acid or vector encoding an RNA-guided DNA nuclease described herein, such as a Cas nuclease (e.g., Cas9). The RNA-guided DNA nuclease can be Streptococcus pyogenes Cas9. In a specific embodiment, the guide RNA is chemically modified. In some embodiments, the guide RNA and the nucleic acid encoding the RNA-guided DNA nuclease are administered in an LNP described herein, such as an LNP comprising a CCD lipid (e.g., an amine lipid such as lipid A), a helper lipid (e.g., cholesterol), a stealth lipid (e.g., a PEG lipid such as PEG2k-DMG), and optionally a neutral lipid (e.g., DSPC).
[0185] In some embodiments, the present application describes a method of reducing TTR serum concentration, comprising administering a guide RNA as described herein, for example, having any one or more guide sequences of SEQ ID NO: 1-81 or SEQ ID NO: 275-307, or any one or more sgRNAs of SEQ ID NO: 171-251 or SEQ ID NO: 341-373. In some embodiments, a gRNA comprising any one or more guide sequences of SEQ ID NO: 1-81 or SEQ ID NO: 275-307 or any one or more sgRNAs of SEQ ID NO: 171-251 or SEQ ID NO: 341-373 is administered to reduce or prevent TTR accumulation (amyloid deposition) in amyloid or amyloid fibrils. The gRNA is administered with a nucleic acid or vector encoding an RNA-guided DNA nuclease described herein, such as a Cas nuclease (e.g., Cas9). The RNA-guided DNA nuclease can be Streptococcus pyogenes Cas9. In a specific embodiment, the guide RNA is chemically modified. In some embodiments, the guide RNA and the nucleic acid encoding the RNA-guided DNA nuclease are administered in an LNP described herein, such as an LNP comprising a CCD lipid (e.g., an amine lipid such as lipid A), a helper lipid (e.g., cholesterol), a stealth lipid (e.g., a PEG lipid such as PEG2k-DMG), and optionally a neutral lipid (e.g., DSPC).
[0186] In some embodiments, the present application describes a method of reducing TTR serum concentration, comprising administering a guide RNA as described herein, for example, comprising any one or more guide sequences of SEQ ID NO: 1-81 or SEQ ID NO: 275-307, or any one or more sgRNAs of SEQ ID NO: 171-251 or SEQ ID NO: 341-373. In some embodiments, a gRNA comprising any one or more guide sequences of SEQ ID NO: 1-81 or SEQ ID NO: 275-307, or any one or more sgRNAs of SEQ ID NO: 171-251 or SEQ ID NO: 341-373 is administered to reduce or prevent TTR accumulation (amyloid deposition) in amyloid or amyloid fibrils. The gRNA is administered with a nucleic acid or vector encoding an RNA-guided DNA nuclease described herein, such as a Cas nuclease (e.g., Cas9). The RNA-guided DNA nuclease can be Streptococcus pyogenes Cas9. In a specific embodiment, the guide RNA is chemically modified. In some embodiments, the guide RNA and the nucleic acid encoding the RNA-guided DNA nuclease are administered in an LNP described herein, such as an LNP comprising a CCD lipid (e.g., an amine lipid such as lipid A), a helper lipid (e.g., cholesterol), a stealth lipid (e.g., a PEG lipid such as PEG2k-DMG), and optionally a neutral lipid (e.g., DSPC).
[0187] In some embodiments, the present application describes a method of reducing or preventing TTR accumulation in amyloid or amyloid fibrils in a subject, comprising administering a composition comprising a guide RNA described herein (e.g., having any one or more guide sequences of SEQ ID NOs: 1-81 or SEQ ID NOs: 275-307) or any one or more sgRNAs of SEQ ID NOs: 171-251 or SEQ ID NOs: 341-373. In some embodiments, a method of reducing or preventing TTR accumulation in amyloid or amyloid fibrils in a subject is provided, comprising administering a composition comprising any one or more sgRNAs of SEQ ID NOs: 171-251 or SEQ ID NOs: 341-373. In some embodiments, a gRNA comprising any one or more guide sequences of SEQ ID NO: 1-81 or SEQ ID NO: 275-307 or any one or more sgRNA of SEQ ID NO: 171-251 or SEQ ID NO: 341-373 is administered to reduce or prevent TTR accumulation (amyloid deposition) in amyloid or amyloid fibrils. The gRNA is administered together with a nucleic acid or vector encoding an RNA-guided DNA nuclease described herein, such as a Cas nuclease (e.g., Cas9). The RNA-guided DNA nuclease can be Streptococcus pyogenes Cas9. In a specific embodiment, the guide RNA is chemically modified. In some embodiments, the guide RNA and the nucleic acid encoding the RNA-guided DNA nuclease are administered in an LNP described herein, such as an LNP comprising a CCD lipid (e.g., an amine lipid, such as lipid A), a helper lipid (e.g., cholesterol), a stealth lipid (e.g., a PEG lipid, such as PEG2k-DMG) and an optional neutral lipid (e.g., DSPC).
[0188] In some embodiments, the present application describes a method of reducing or preventing TTR accumulation (amyloid deposition) in amyloid or amyloid fibrils in a subject, comprising administering a composition comprising a guide RNA as described herein (e.g., having any one or more guide sequences of SEQ ID NO: 1-81 or SEQ ID NO: 275-307) or any one or more sgRNAs of SEQ ID NO: 171-251 or SEQ ID NO: 341-373. In some embodiments, a method of reducing or preventing TTR accumulation (amyloid deposition) in amyloid or amyloid fibrils in a subject is provided, comprising administering a composition comprising any one or more sgRNAs of SEQ ID NO: 171-251 or SEQ ID NO: 341-373. In some embodiments, a gRNA comprising any one or more guide sequences of SEQ ID NO: 1-81 or SEQ ID NO: 275-307 or any one or more sgRNA of SEQ ID NO: 171-251 or SEQ ID NO: 341-373 is administered to reduce or prevent TTR accumulation (amyloid deposition) in amyloid or amyloid fibrils. The gRNA is administered together with a nucleic acid or vector encoding an RNA-guided DNA nuclease described herein, such as a Cas nuclease (e.g., Cas9). The RNA-guided DNA nuclease can be Streptococcus pyogenes Cas9. In a specific embodiment, the guide RNA is chemically modified. In some embodiments, the guide RNA and the nucleic acid encoding the RNA-guided DNA nuclease are administered in an LNP described herein, such as an LNP comprising a CCD lipid (e.g., an amine lipid, such as lipid A), a helper lipid (e.g., cholesterol), a stealth lipid (e.g., a PEG lipid, such as PEG2k-DMG) and an optional neutral lipid (e.g., DSPC).
[0189] In some embodiments, the gRNA includes a guide sequence of Table 3, is used with an RNA-guided DNA nuclease (such as a Cas nuclease translated from a nucleic acid) to induce DSB, and non-homologous end joining (NHEJ) during repair results in a TTR gene mutation. In some embodiments, NHEJ results in a deletion or insertion of nucleotides, thereby inducing a frameshift or nonsense mutation in the TTR gene.
[0190] In some embodiments, administration of a guide RNA and a nucleic acid encoding an RNA-guided DNA binder (e.g., in a composition provided herein) reduces TTR levels (e.g., serum levels) in a subject and thereby prevents accumulation and aggregation of TTR in amyloid or amyloid fibrils (amyloid deposition).
[0191] In some embodiments, reducing or preventing TTR accumulation in amyloid or amyloid fibrils (amyloid deposition) in a subject includes reducing or preventing TTR deposition in one or more tissues of the subject, such as the liver, stomach, colon, or neural tissue. In some embodiments, the neural tissue includes the sciatic nerve or dorsal root ganglion. In some embodiments, TTR deposition is reduced in two, three, or four of the stomach, colon, dorsal root ganglion, and sciatic nerve. The level of deposition in a given tissue can be determined using a biopsy sample (e.g., using immunostaining). In some embodiments, reducing or preventing TTR accumulation in amyloid or amyloid fibrils in a subject and / or reducing or preventing TTR deposition is inferred based on reducing serum TTR levels over a period of time. As discussed in the Examples, it has been found that reducing serum TTR levels according to the methods and uses provided herein can result in the removal of deposited TTR from tissues, such as those discussed above and in the Examples, for example, when measured 8 weeks after administration of the composition.
[0192] In some embodiments, amyloid deposition is reduced by 30% to 35%, 35% to 40%, 40% to 45%, 45% to 50%, 50% to 55%, 55% to 60%, 60% to 65%, 65% to 70%, 70% to 75%, 75% to 80%, 80% to 85%, 85% to 90%, 90% to 95%, or 95% to 99% compared to amyloid deposition observed in the subject before administration of the composition. In some embodiments, amyloid deposition is reduced by 30%-95%, 40%-90%, or 50%-85%, 30%-60%, 40%-80%, 50%-75%, or 60%-90% compared to amyloid deposition observed in the subject before administration of the composition.
[0193] In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a cow, pig, monkey, sheep, dog, cat, fish, or poultry. In some embodiments, the subject is a companion animal or a livestock animal.
[0194] In some embodiments, one or more guide RNAs described herein (e.g., including one or more guide sequences in Table 3 (e.g., in a composition provided herein)) and a nucleic acid encoding an RNA-guided DNA binder described herein (e.g., mRNA) are provided for the preparation of a medicament for treating a human subject with ATTR. The RNA-guided DNA binder can be Cas9, such as Streptococcus pyogenes Cas9. In specific embodiments, the guide RNA is chemically modified.
[0195] In some embodiments, the composition comprising the guide RNA and the nucleic acid is administered intravenously. In some embodiments, the composition comprising the guide RNA and the nucleic acid is administered into the hepatic circulation.
[0196] In some embodiments, a single administration of a composition comprising a guide RNA and a nucleic acid provided herein is sufficient to knock down the expression of a mutant protein. In some embodiments, a single administration of a composition comprising a guide RNA and a nucleic acid provided herein is sufficient to knock out the expression of a mutant protein in a cell population. In other embodiments, more than one administration of a composition comprising a guide RNA and a nucleic acid provided herein can be beneficial for maximizing editing by a cumulative effect. For example, a composition provided herein can be administered 2, 3, 4, 5 or more times, such as 2 times. Administration can be spaced for a period of time, for example, 1 day to 2 years, such as 1 to 7 days, 7 to 14 days, 14 days to 30 days, 30 days to 60 days, 60 days to 120 days, 120 days to 183 days, 183 days to 274 days, 274 days to 366 days or 366 days to 2 years.
[0197] In some embodiments, the effective amount of the composition administered is in the range of 0.01 to 10 mg / kg (mpk), for example 0.01 to 0.1 mpk, 0.1 to 0.3 mpk, 0.3 to 0.5 mpk, 0.5 to 1 mpk, 1 to 2 mpk, 2 to 3 mpk, 3 to 5 mpk, 5 to 10 mpk or 0.1, 0.2, 0.3, 0.5, 1, 2, 3, 5 or 10 mpk. In some embodiments, the amount of the composition administered is 2-4 mg / kg, such as 2.5-3.5 mg / kg. In some embodiments, the amount of the composition administered is about 3 mg / kg.
[0198] In some embodiments, the efficacy of treatment with the compositions described herein is assessed 1 year, 2 years, 3 years, 4 years, 5 years, or 10 years after delivery. In some embodiments, the efficacy of treatment with the compositions described herein is assessed by measuring serum levels of TTR (monomer and / or tetramer) before and after treatment. In some embodiments, the efficacy of treatment with the compositions described herein as assessed by reducing serum levels of TTR is observed at 1 week, 2 weeks, 3 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, or 11 months. In some embodiments, the level of monomer, dimer, and / or tetramer TTR is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99%.
[0199] In some embodiments, treatment slows or stops disease progression.
[0200] In some embodiments, treatment slows or stops the progression of FAP. In some embodiments, treatment results in improvement, stabilization, or slowing of changes in symptoms of sensorimotor neuropathy or autonomic neuropathy.
[0201] In some embodiments, treatment results in improvement, stabilization, or slowing of changes in FAC symptoms. In some embodiments, treatment results in improvement, stabilization, or slowing of changes in restrictive cardiomyopathy or congestive heart failure symptoms.
[0202] In some embodiments, efficacy of treatment is measured by increased survival time of the subject.
[0203] In some embodiments, the efficacy of treatment is measured by an improvement or slowing of progression of symptoms of sensorimotor or autonomic neuropathy. In some embodiments, the efficacy of treatment is measured by an increase or slowing of decrease in the ability to move a part of the body or feel any part of the body. In some embodiments, the efficacy of treatment is measured by an improvement or slowing of decrease in the ability to: swallow; breathe; use an arm, hand, leg, or foot; or walk. In some embodiments, the efficacy of treatment is measured by an improvement or slowing of progression of neuropathic pain. In some embodiments, neuropathic pain is characterized by pain, burning, tingling, or abnormal sensations.
[0204] In some embodiments, the efficacy of treatment is measured by an improvement or slowing of increase in orthostatic hypotension, dizziness, gastrointestinal dysmotility, bladder dysfunction, or sexual dysfunction. In some embodiments, the efficacy of treatment is measured by an improvement or slowing of progression of weakness. In some embodiments, the efficacy of treatment is measured using electromyography, nerve conduction testing, or patient-reported outcomes.
[0205] In some embodiments, the efficacy of treatment is measured by improvement or slowing of progression of symptoms of congestive heart failure or CHF. In some embodiments, the efficacy of treatment is measured by reduction or slowing of increase in shortness of breath, dyspnea, fatigue, or swelling of the ankles, feet, legs, abdomen, or swelling of the neck veins. In some embodiments, the efficacy of treatment is measured by improvement or slowing of progression of fluid accumulation in the body, which can be assessed by indicators such as weight gain, frequent urination, or nighttime coughing. In some embodiments, the efficacy of treatment is measured using cardiac biomarker tests (such as type 13 natriuretic peptide [BNP] or N-terminal pro B-type natriuretic peptide [NT-proBNP]), lung function tests, chest x-rays, or electrocardiograms.
[0206] Additional treatment
[0207] In some embodiments, combination therapies are described that include administering any one of the gRNAs described herein, e.g., comprising any one or more guide sequences disclosed in Table 3, and a nucleic acid encoding an RNA-guided DNA binder as described herein, such as a nucleic acid (e.g., mRNA) or vector encoding S. pyogenes Cas9 described herein (e.g., in a composition provided herein), and an additional therapy suitable for alleviating ATTR symptoms.
[0208] In some embodiments, the add-on therapy for ATTR is a treatment for sensorimotor or autonomic neuropathy. In some embodiments, the treatment for sensorimotor or autonomic neuropathy is a nonsteroidal anti-inflammatory drug, an antidepressant, an anticonvulsant, an antiarrhythmic, or an anesthetic. In some embodiments, the antidepressant is a tricyclic or a serotonin-norepinephrine reuptake inhibitor. In some embodiments, the antidepressant is amitriptyline, duloxetine, or venlafaxine. In some embodiments, the anticonvulsant is gabapentin, pregabalin, topiramate, or carbamazepine. In some embodiments, the add-on therapy for sensorimotor neuropathy is transcutaneous electrical nerve stimulation.
[0209] In some embodiments, the additional therapy for ATTR is the treatment of restrictive cardiomyopathy or congestive heart failure (CHF). In some embodiments, the treatment of CHF is ACE inhibitors, aldosterone antagonists, angiotensin receptor blockers, beta blockers, digoxin, diuretics or isosorbide dinitrate / hydralazine hydrochloride. In some embodiments, ACE inhibitors are enalapril, captopril, ramipril, perindopril, imidapril or quinapril. In some embodiments, aldosterone antagonists are eplerenone or spironolactone. In some embodiments, angiotensin receptor blockers are azilsartan, cardesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan or valsartan. In some embodiments, beta blockers are acebutolol, atenolol, bisoprolol, metoprolol, nadolol, nebivolol or propranolol. In some embodiments, the diuretic is chlorothiazide, chlorthalidone, hydrochlorothiazide, indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, or aminoamphetamine.
[0210] In some embodiments, the combination therapy comprises administering any one of the gRNAs comprising any one or more guide sequences disclosed in Table 3 and a nucleic acid encoding an RNA-guided DNA binder (e.g., in a composition provided herein) and an siRNA targeting TTR or mutant TTR. In some embodiments, the siRNA is any siRNA capable of further reducing or eliminating wild-type or mutant TTR expression. In some embodiments, the siRNA is the drug Patisiran (ALN-TTR02) or ALN-TTRsc02. In some embodiments, the siRNA is administered after any one of the gRNAs comprising any one or more guide sequences disclosed in Table 3 (e.g., in a composition provided herein). In some embodiments, the siRNA is administered periodically after treatment with any of the gRNA compositions provided herein.
[0211] In some embodiments, the combination therapy comprises administering any one of the gRNAs comprising any one or more guide sequences described herein (e.g., disclosed in Table 3) and nucleic acids encoding RNA-guided DNA binders described herein (e.g., in compositions provided herein) and antisense nucleotides targeting TTR or mutant TTR. In some embodiments, the antisense nucleotide is any antisense nucleotide that can further reduce or eliminate wild-type or mutant TTR expression. In some embodiments, the antisense nucleotide is the drug Inotersen (IONS-TTRRx). In some embodiments, the antisense nucleotide is administered after any one of the gRNAs comprising any one or more guide sequences disclosed in Table 3 and nucleic acids encoding RNA-guided DNA binders (e.g., in compositions provided herein). In some embodiments, antisense nucleotides are administered periodically after treatment with any of the gRNA compositions provided herein.
[0212] In some embodiments, the combination therapy comprises administering any one of the gRNAs comprising any one or more guide sequences disclosed in Table 3 and a nucleic acid encoding an RN-guided DNA binder (e.g., in a composition provided herein) and a small molecule stabilizer that promotes kinetic stabilization of the properly folded tetrameric form of TTR.
[0213] In some embodiments, the small molecule stabilizer is the drug clofazodone Or diflunisal. In some embodiments, the small molecule stabilizer is administered after any gRNA comprising any one or more guide sequences disclosed in Table 3 (e.g., in a composition provided herein). In some embodiments, the small molecule stabilizer is administered regularly after treatment with any composition provided herein.
[0214] In some embodiments, the combination therapy comprises administering any one of the gRNAs comprising any one or more guide sequences disclosed in Table 3 and a nucleic acid encoding an RNA-guided DNA binder (e.g., in a composition provided herein) and any compound disclosed in Müller ML et al., European Journal of Heart Failure (2020) 22, 39–53. For example, the compound is a TTR tetramer stabilizer such as clofentacil (Vyndaqel), diflunisal, or epigallocatechin-3-gallate (EGCG); a TTR silencing agent such as Inotersen (Tegsedi) or Patisiran (Onpattro); a fibril disruptor such as doxycycline, tauroursodeoxycholic acid (TUDCA); or a monoclonal antibody such as an anti-TTR antibody or an anti-serum amyloid P (SAP) antibody (Dezamizumab).
[0215] In any of the aforementioned embodiments, the guide sequence disclosed in Table 3, and / or the guide RNA can be a chemically modified guide RNA.
[0216] In some embodiments, the methods described herein include an infusion prophylactic agent. In some embodiments, the infusion prophylactic agent is administered to the subject before the gene editing composition. In some embodiments, the infusion prophylactic agent is administered to the subject 8-24 hours or 1-2 hours before the administration of the nucleic acid composition.
[0217] In some embodiments, the infusion preventive comprises a corticosteroid. In some embodiments, the infusion preventive comprises one or more or all of a corticosteroid, an antipyretic (e.g., oral acetaminophen (also known as paracetamol), which can relieve pain and fever and / or inhibit COX enzymes and / or prostaglandins), a HI blocker or an H2 blocker. In some embodiments, the infusion preventive comprises an intravenous corticosteroid (e.g., dexamethasone 8-12 mg, such as 10 mg, or equivalent) and an antipyretic (e.g., oral acetaminophen or paracetamol 500 mg). In some embodiments, HI blockers (e.g., diphenhydramine 50 mg or equivalent) and / or H2 blockers (e.g., ranitidine 50 mg or equivalent) are administered orally. In some embodiments, HI blockers (e.g., diphenhydramine 50 mg or equivalent) and / or H2 blockers (e.g., ranitidine 50 mg or equivalent) are administered intravenously. In some embodiments, the infusion prophylactic agent is administered intravenously 1-2 hours prior to infusion of the nucleic acid composition.
[0218] In some embodiments, an intravenous HI blocker and / or an intravenous H2 blocker is replaced by an oral equivalent. Infusion prophylactics can be used to reduce adverse reactions associated with the administration of nucleic acid compositions. In some embodiments, infusion prophylactics are administered as a premedication required before administering a nucleic acid composition. The dosage, frequency, and mode of administration of corticosteroids, infusion prophylactics, and compositions containing guide RNAs described herein can be independently controlled.
[0219] The corticosteroid used in the disclosed method can be administered according to protocols known in the art (e.g., protocols approved by the U.S. FDA). In some embodiments, for example, administered to a human subject or for a human subject, the amount of the corticosteroid administered can range from about 0.75 mg to about 25 mg. In some embodiments, for example, administered to a human subject or for a human subject, the amount of the corticosteroid administered can range from about 0.01-0.5 mg / kg, such as 0.1-0.40 mg / kg or 0.25-0.40 mg / kg.
[0220] In some embodiments, the corticosteroid is administered before the composition containing the guide RNA described herein. In some embodiments, the corticosteroid is administered after the composition containing the guide RNA described herein. In some embodiments, the corticosteroid is administered simultaneously with the composition containing the guide RNA described herein. In some embodiments, multiple doses of the corticosteroid are administered before or after the administration of the composition containing the guide RNA. In some embodiments, multiple doses of the composition containing the guide RNA are administered before or after the administration of the corticosteroid. In some embodiments, multiple doses of the corticosteroid and multiple doses of the composition containing the guide RNA are administered.
[0221] If appropriate, a dose of corticosteroid can be administered as at least two subdoses separated by appropriate intervals. In some embodiments, corticosteroids are administered at least twice before administering a composition containing a guide RNA as described herein. In some embodiments, a dose of corticosteroids is administered at least twice after administering a composition containing a guide RNA as described herein. In some embodiments, corticosteroids are administered at intervals of 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours, 18 hours; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 days; 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 weeks; or an interval of time within the range defined by any two of the foregoing values (e.g., before, simultaneously and / or after administering a composition containing a guide RNA as described herein). In some embodiments, the corticosteroid is administered prior to administration of a composition containing a guide RNA described herein at an interval of 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours, 18 hours; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 days; 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 weeks; or an amount of time within a range defined by any two of the foregoing values. In some embodiments, the corticosteroid is administered after administration of a composition containing a guide RNA described herein at an interval of 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours, 18 hours; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 days; 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 weeks; or an amount of time within a range defined by any two of the foregoing values.
[0222] In some embodiments, the corticosteroid is administered at least twice. In some embodiments, the corticosteroid is administered at least three times. In some embodiments, the corticosteroid is administered at least four times. In some embodiments, the corticosteroid is administered up to five, six, seven, eight, nine, or ten times. The first dose can be oral, and the second or subsequent doses can be parenteral, such as infusion. Alternatively, the first dose can be parenteral, and the second or subsequent doses can be oral.
[0223] In some embodiments, the corticosteroid is administered orally prior to the intravenous administration of a composition containing a guide RNA described herein. In some embodiments, the corticosteroid is administered orally during or after the intravenous administration of a composition containing a guide RNA described herein.
[0224] In some embodiments, the corticosteroid is dexamethasone. In some embodiments, dexamethasone is administered intravenously 1-2 hours before the infusion of the nucleic acid composition. In some embodiments, 8-12 mg, such as 10 mg of dexamethasone, is administered intravenously 1-2 hours before the infusion of the nucleic acid composition. In some embodiments, dexamethasone is orally administered 8 to 24 hours before the infusion of the nucleic acid composition. In some embodiments, 8-12 mg, such as 8 mg of dexamethasone, is orally administered 8 to 24 hours before the infusion of the nucleic acid composition. In some embodiments, 8-12 mg, such as 8 mg of dexamethasone, is orally administered 8 to 24 hours before the infusion of the nucleic acid composition, and 8-12 mg, such as 10 mg of dexamethasone, is administered intravenously 1-2 hours before the infusion of the nucleic acid composition.
[0225] Delivery of Nucleic Acid Compositions
[0226] In some embodiments, the nucleic acid compositions described herein include gRNA and nucleic acids encoding RNA-guided DNA binders (encoded as RNA or on one or more vectors), which are formulated in or administered by lipid nanoparticles (LNPs); see, e.g., WO2017173054A1 and WO2019067992A1, the contents of which are incorporated herein by reference in their entirety. Any LNP known to those skilled in the art capable of delivering nucleotides to a subject can be used with guide RNAs described herein and nucleic acids encoding RNA-guided DNA nucleases.
[0227] In some embodiments, the guide RNA and the nucleic acid encoding the RNA-guided DNA nuclease are administered in an LNP described herein, such as an LNP comprising a CCD lipid (e.g., an amine lipid such as lipid A), a helper lipid (e.g., cholesterol), a stealth lipid (e.g., a PEG lipid such as PEG2k-DMG), and optionally a neutral lipid (e.g., DSPC).
[0228] Various embodiments of LNP preparations for RNA (including CRISPR / Cas payloads) are disclosed herein. Such LNP preparations may include (i) CCD lipids, such as amine lipids, (ii) neutral lipids, (iii) auxiliary lipids, and (iv) stealth lipids, such as PEG lipids. Some embodiments of LNP preparations include amine lipids, as well as auxiliary lipids, neutral lipids and stealth lipids (such as PEG lipids). In some embodiments, the LNP preparation includes less than 1% of neutral phospholipids. In some embodiments, the LNP preparation includes less than 0.5% of neutral phospholipids. "Lipid nanoparticles" can be particles comprising multiple (i.e., more than one) lipid molecules, which are physically associated with each other by intermolecular forces. CCD lipids, amine lipids, neutral lipids and other lipids that can be used in LNP preparations disclosed herein are described in WO2020198697, WO2015006747, WO2016118724 and WO2021026358, which are all incorporated herein in their entirety.
[0229] In some embodiments, the nucleic acid compositions described herein are formulated in or administered by lipid nanoparticles (LNPs) comprising ALC0315, DSPC, cholesterol, and DMG-PEG2000. In some embodiments, the N / P ratio of the LNP is about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, the N / P ratio is about 3 to about 7. The N / P ratio is the molar ratio between the amine (N, which becomes a cation at low pH) on the ionizable lipid and the phosphate (P, anion) on the RNA backbone. The N / P ratio can affect the encapsulation efficiency and biological activity of the LNP formulations comprising RNA.
[0230] In some embodiments, ALC0315 accounts for 40 mol% to 60 mol% of the total lipids present in the particle, DSPC accounts for 5 mol% to 15 mol% of the total lipids present in the particle, cholesterol accounts for 30 mol% to 50 mol% of the total lipids present in the particle, and DMG-PEG2000 accounts for 1 mol% to 5 mol% of the total lipids present in the particle. In one embodiment, the LNP comprises ALC0315, DSPC, cholesterol and DMG-PEG2000 in a molar ratio of 50:9.5:37.5:3.
[0231] More technologies that can be used to deliver the composition of the present application include technologies encapsulated using biodegradable polymers, liposomes or nanoparticles. In some embodiments, the composition of the present application is applied with any suitable delivery vehicle, including but not limited to polymers, engineered viral particles (e.g., adeno-associated virus), exosomes, liposomes, supercharged proteins, implantable devices or red blood cells. Suitable delivery methods are described in US10851357, US10709797 and US20170349914, each of which is incorporated herein in its entirety.
[0232] Example
[0233] Unless otherwise indicated, the practice of the methods and compositions of the present application employs conventional techniques of molecular biology (including recombinant techniques), cell culture, immunology, cell biology, and biochemistry, which are well within the capabilities of those skilled in the art. Such techniques are explained in the literature, such as "Molecular Cloning: A Laboratory Manual", second edition (Sambrook, 1989); "Oligonucleotide Synthesis" (Gait, 1984); "Animal Cell Culture" (Freshney, 1987); "Methods in Enzymology" "Handbook of Experimental Immunology" (Weir, 1996); "Gene Transfer Vectors for Mammalian Cells" (Miller and Calos, 1987); "Current Protocols in Molecular Biology" (Ausubel, 1987); "PCR: The Polymerase Chain Reaction", (Mullis, 1994); "Current Protocols in Immunology" (Coligan, 1991). These techniques are applicable to the methods and compositions of the present application. The following sections will discuss particularly useful techniques for specific embodiments. The materials, reagents and methods further described below are used in the following examples. The embodiments described in the following examples do not limit the scope of the claims.
[0234] Example 1. Design of guide RNA sequence
[0235] Initial guide selection was performed in silico using CRISPOR (CRISPOR (tefor.net)), a web tool for genome editing experiments using the CRISPR-Cas9 system. CRISPOR finds guide RNAs in the input sequence and ranks them according to different scores to assess potential off-targets in the genome of interest and predict on-target activity. Initial guide selection was performed using the human reference genome - Homo sapiens (human) genome assembly GRCh38.p13 (hg38) and user-defined genomic regions of interest (e.g., TTR protein-coding exons, promoters, regulatory regions, etc.) to identify PAMs (NGG) in the regions of interest. For each selected PAM, an analysis was performed and statistics were reported. gRNA molecules were further selected and ranked according to a number of criteria (e.g., GC content, predicted on-target activity, and potential off-target activity). ART-Design refers to the prepared guide sequences. Table 3 below shows the 118 guide sequences designed for these targeted TTR genes. The corresponding sgRNAs are shown in Table 4.
[0236] Table 3: Boot sequence
[0237]
[0238]
[0239]
[0240]
[0241]
[0242]
[0243]
[0244] Note: The character "f" in the polynucleotide sequence disclosed herein represents a 2' fluoro base, wherein the base has a fluorine-modified ribose. "f" represents a fluorine modification of the base immediately following "f" in the polynucleotide sequence, for example, CUfGATU contains a 2' fluoroG.
[0245] Table 4: crRNA and sgRNA sequences corresponding to the guide sequences in Table 3
[0246]
[0247]
[0248]
[0249]
[0250]
[0251]
[0252]
[0253]
[0254]
[0255]
[0256]
[0257]
[0258]
[0259]
[0260]
[0261]
[0262] The 118 sgRNA sequences shown in Table 4 (SEQ ID NOs: 171-255 and 341-373) were further tested in in vitro and in vivo assays.
[0263] Example 2. Selection of gRNAs that exhibit high editing efficiency in cell lines
[0264] Various sgRNAs in Table 4 (SEQ ID NOs: 171-255 and 341-373) were screened for gene editing efficacy in multiple cell types electroporated with ribonucleoprotein (RNP) complexes containing spCas9 protein and the synthetic sgRNAs shown in Table 4 or lipofected with spCas9 mRNA and the synthetic sgRNAs shown in Table 4, which target human TTR. The editing percentage of sgRNAs containing each guide sequence in each cell type was determined, and the guide sequences were then ranked according to the highest editing percentage. The following materials and methods were used in this study.
[0265] In vitro delivery of spCas9 protein and sgRNA
[0266] GRNA modification. The last three nucleotides at the 5' end and the 3' end are both 2'-O-methyl (2'-O-Me) modified. There is a phosphorothioate (PS) bond between the last four nucleotides at the 5' end and the 3' end, and additional modifications or substitutions such as deoxyribonucleotides or 2'F are specifically noted in the examples.
[0267] HEK293 cell line. Human embryonic renal adenocarcinoma cell line was cultured in DMEM medium supplemented with 10% fetal bovine serum. 24 hours before electroporation, cells were seeded in 6-well plates at a density of 800,000-2,000,000 cells / well or in 96-well plates at a density of 8,000-20,000 cells / well. Cells were electroporated using a Celetrix electroporator (Celetrix, CTX-1500A) according to the supplier's protocol. Cells were electroporated using an RNP complex containing Cas9 nuclease (5-50 pmol), sgRNA (10-500 pmol) and Celetrix buffer.
[0268] HepG2 cell line. The human hepatocellular carcinoma cell line HepG2 was cultured in DMEM medium supplemented with 10% fetal bovine serum. 24 hours before electroporation, the cells were seeded in 6-well plates at a density of 1,000,000-1,500,000 cells / well or in 96-well plates at a density of 8,000-22,000 cells / well. The cells were electroporated using a Celetrix electroporator (Celetrix, CTX-1500A) according to the supplier's protocol. The cells were electroporated using an RNP complex containing Cas9 nuclease (5-50 pmol), sgRNA (10-500 pmol), and Celetrix buffer.
[0269] Huh7 cell line. Human hepatocellular carcinoma cell line Huh7 was cultured in DMEM medium supplemented with 10% fetal bovine serum. 24 hours before electroporation, cells were seeded in 6-well plates at a density of 500,000-1,500,000 cells / well or in 96-well plates at a density of 5,000-15,000 cells / well. Cells were electroporated using a Celetrix electroporator (Celetrix, CTX-1500A) according to the supplier's protocol. Cells were electroporated using an RNP complex containing Cas9 nuclease (5-50 pmol), sgRNA (10-500 pmol), and Celetrix buffer.
[0270] In vitro delivery of spCas9 mRNA and sgRNA
[0271] HEK293 cell line. Human embryonic kidney adenocarcinoma cell line was cultured in DMEM medium supplemented with 10% fetal bovine serum. 24 hours before transfection, cells were seeded in 6-well plates at a density of 800,000-2,000,000 cells / well, or in 96-well plates at a density of 8,000-20,000 cells / well. Cells were transfected with Lipofectamine 3000 (ThermoFisher, catalog number L3000001) according to the supplier's protocol. Cells were transfected with a lipid complex containing 0.5-500ng Cas9 mRNA, 1-1,000ng sgRNA, and Lipofectamine 3000.
[0272] HepG2 cell line. The human hepatocellular carcinoma cell line HepG2 was cultured in DMEM medium supplemented with 10% fetal bovine serum. 24 hours before transfection, the cells were seeded in 6-well plates at a density of 1,000,000-1,500,000 cells / well, or in 96-well plates at a density of 8,000-22,000 cells / well. Cells were transfected with Lipofectamine RNAiMAX (ThermoFisher, catalog number 13778075) according to the supplier's protocol. Cells were transfected with a lipid complex containing 1-500ng Cas9mRNA, 2-1,000ng sgRNA, and Lipofectamine RNAiMAX.
[0273] Huh7 cell line. Human hepatocellular carcinoma cell line Huh7 was cultured in DMEM medium supplemented with 10% fetal bovine serum. 24 hours before transfection, cells were seeded in 6-well plates at a density of 500,000-1,500,000 cells / well, or in 96-well plates at a density of 5,000-15,000 cells / well. Cells were transfected with Lipofectamine MessengerMAX (ThermoFisher, catalog number LMRNA003) according to the supplier's protocol. Cells were transfected with lipid complexes containing 1-500ng Cas9 mRNA, 2-1,000ng sgRNA, and Lipofectamine MessengerMAX.
[0274] Primary human and cynomolgus monkey hepatocytes. Primary human hepatocytes (PHH) (thermofisher or BioIVT) and primary cynomolgus monkey hepatocytes (PCH) (BioIVT) were cultured according to the supplier's protocol. Briefly, the cells were thawed and resuspended in hepatocyte thawing medium supplemented with supplements, and then centrifuged at 100g for 10 minutes for human hepatocytes and 80g for 4 minutes for cynomolgus monkey hepatocytes. The supernatant was discarded and the precipitated cells were resuspended in hepatocyte seeding medium supplemented with supplements. The cells were counted and seeded at a density of 60,000 cells / well on Bio-coat collagen I coated 96-well plates (ThermoFisher, catalog number 877272). The seeded cells were allowed to settle and grow adherently in a tissue culture incubator at 37°C and 5% CO2 atmosphere for 6 or 24 hours. After culture, the cells were checked for monolayer formation and the medium was replaced with hepatocyte medium containing a serum-free supplement pack. The next day, cells were transfected with Lipofectamine RNAiMAX (ThermoFisher, catalog number 13778075) according to the supplier's protocol. Cells were transfected with lipid complexes containing 1-500 ng Cas9 mRNA, 2-1,000 ng sgRNA, and Lipofectamine RNAiMAX.
[0275] Transthyretin (TTR) ELISA analysis in cultured cells
[0276] Cell (HepG2 or Huh7) supernatants or lysates were collected and separated, and TTR expression levels were determined using a human prealbumin (transthyretin) ELISA kit (Abcam, catalog number ab231920) according to the supplier's protocol. In brief, when measuring human TTR, the sample was serially diluted with the kit sample diluent to a final dilution of 5,000 times. 100uL of the prepared standard curve or diluted serum sample was added to the ELISA plate, incubated at room temperature for 30 minutes, and then washed 3 times with the provided wash buffer. Then 100uL of detection antibody was added to each well, incubated at room temperature for 20 minutes, and then washed 3 times. 100uL of substrate was added, then incubated at room temperature for 10 minutes, and then 100ul of stop solution was added. The absorbance of the contents was measured using a Spectramax M5 plate reader and analyzed using SoftmaxPro version 7.0 software. Serum TTR levels were calculated from the standard curve using a 4-parameter logistic fit and expressed as serum ng / mL or knockdown percentage relative to control (vehicle-treated) cells.
[0277] Western blot analysis of intracellular TTR
[0278] Human hepatocellular carcinoma cell line HepG2 was transfected as described previously. Six days after transfection, the culture medium was removed and the cells were lysed with 50 μl RIPA buffer and a freshly added protease inhibitor mixture consisting of a full protease inhibitor mixture (Sigma, catalog number 11697498001), 1 mM DTT and 250 U / ml Benzonase (EMD Millipore, catalog number 71206-3). The cells were placed on ice for 30 minutes, at which time NaCl (final concentration of 1 M) was added. The cell lysate was mixed thoroughly and kept on ice for 30 minutes. The whole cell extract ("WCE") was transferred to a PCR plate and centrifuged to precipitate debris. The protein content of the lysate was assessed using the BCA assay (UU-BIO, catalog number U10007A). The BCA assay procedure was completed according to the supplier's protocol. The extract was stored at minus 20°C before use. Western blot was performed to assess intracellular TTR protein levels. The lysate was denatured at 95°C for 10 minutes. Western blots were run on 8-12% Bis-Tris gels (Genscript) using the eZwest system according to the supplier's protocol. Blots were rinsed with TBST and probed with rabbit α-TTR monoclonal antibody (Abcam, catalog number Ab75815) (1:2000 in TBST). β-Actin (1:5000 in TBST) was applied as a loading control (Abcam, catalog number ab8226) and incubated simultaneously with the TTR primary antibody. Blots were incubated and rinsed in TBST and probed with secondary antibodies for mouse and rabbit (ThermoFisher, catalog number PI35518 and PISA535571) (both 1:25,000 in TBST) for 30 minutes at room temperature. After incubation, blots were rinsed 3 times in TBST for 5 minutes each and rinsed twice with PBS. Blots were visualized and analyzed using the ePhoto system (Genscript).
[0279] Genomic DNA isolation
[0280] Transfected cells were harvested 72 hours after transfection. PureLink TM Genomic DNA was extracted from each well of a 6-well plate using a genomic DNA mini kit (ThermoFisher, catalog number K182001) or from each 10 cm dish using QuickExtract DNA extraction solution (LGC Lucigen, catalog number QE09050). All DNA samples were subsequently analyzed by Sanger sequencing as described in this article.
[0281] Sanger sequencing analysis
[0282] To quantitatively determine the editing efficiency at target locations in the genome and rapidly screen potential sgRNAs, Sanger sequencing was used to identify the efficiency of edits introduced by gene editing.
[0283] Primers are designed around a target site within a gene of interest (eg, TTR) and the genomic region of interest is amplified.
[0284] Sanger sequencing was performed on a 3730xl DNA Analyzer (ThermoFisher, Cat. No. 3730XL) according to the supplier's protocol. Raw sequencing files (.ab1) were analyzed on online analysis tools (e.g. TIDE: tide.nki.nl / , ICE: ice.synthego.com / ) to determine editing efficiency.
[0285] Next Generation Sequencing (“NGS”) Analysis
[0286] To quantitatively determine the efficiency and pattern of editing at target locations in the genome, sequencing is used to identify the presence of substitutions, insertions, and deletions introduced by gene editing.
[0287] NGS is used to assess the efficiency and pattern of editing at specific genomic target sites. This approach allows for the detection of any insertions, deletions, or substitutions introduced during the gene editing process in a quantitative manner.
[0288] Primers are designed around a target site within a gene of interest (eg, TTR) and the genomic region of interest is amplified.
[0289] According to the Illumina supplier's protocol, additional PCR was performed to add chemicals for sequencing. Subsequently, the amplicon was sequenced using the Illumina NovaSeq 6000 instrument. The resulting reads were compared to a reference genome, which can be a human reference genome (hg38), a cynomolgus monkey reference genome (mf5), a rat reference genome (rn6), or a mouse reference genome (mm39). Reads with low quality scores were eliminated before comparison. The reads were mapped to the reference genome, and only those reads that overlapped with the target region of interest were selected. Wild-type reads and reads containing insertions, substitutions, or deletions were determined and counted.
[0290] The editing percentage, also known as "editing efficiency," "editing percent," or "indel frequency," is determined by dividing the total number of sequence reads with insertions, deletions, or substitutions by the total number of sequence reads including wild-type reads.
[0291] LNP delivery in vivo
[0292] Compositions for delivering the protein and nucleic acid components of CRISPR / Cas to cells, such as cells in a patient, are needed. In particular, compositions that have useful properties for in vitro and in vivo delivery, that can stabilize and deliver RNA components are of interest.
[0293] Herein, we provide compositions based on lipid nanoparticles having useful properties, particularly compositions for delivering CRISPR / Cas gene editing components. The LNP composition comprises: an RNA component; and a lipid component, wherein the lipid component comprises: (1) about 45-55 mol% amine lipids; (2) about 9-11 mol% neutral lipids; and (3) about 1-5 mol% PEG lipids, wherein the remainder of the lipid component is a helper lipid, and wherein the N / P ratio of the LNP composition is about 3 to about 8.
[0294] Unless otherwise stated, each study used 6-8 week old CD-1 female mice or TTR humanized mice. The animals were weighed and grouped according to body weight to prepare the dosing solution according to the average body weight of the group. LNP was administered via the tail vein in an amount of 0.2 ml per animal (approximately 10 ml / kg body weight). Animals were observed daily for adverse reactions. Body weight was measured every other day after administration. Blood was collected by orbital or cardiac puncture at different time points. For studies involving in vivo editing, animals were sacrificed and liver tissue was collected for DNA extraction and analysis.
[0295] Transthyretin (TTR) ELISA Assay for Use in Animal Studies
[0296] Blood was collected and serum was separated. Mouse total TTR and human TTR serum levels were measured using mouse prealbumin ELISA kit (Abcam, catalog number ab282297) and human prealbumin ELISA kit (Abcam, catalog number ab231920), respectively, according to the supplier's protocol.
[0297] Example 3. Targeted sequencing for verification of potential off-target sites
[0298] Potential off-target sites were validated by targeted sequencing of identified potential off-target sites.
[0299] In one approach, HepG2 cells are transfected with Cas9 mRNA and sgRNA as described in Example 1. HepG2 cells are then lysed and primers flanking potential off-target sites are used to generate amplicons for NGS analysis. Identification of a specific level of indels (depending on the overall indel level of all sites) can validate potential off-target sites, while the absence of indels at potential off-target sites may indicate a false positive in the HepG2 dsDNA insertion assay.
[0300] Genomic DNA isolation. Transfected cells were harvested 72 hours after transfection. PureLink TM Genomic DNA was extracted from each well of a 6-well plate using a genomic DNA mini kit (ThermoFisher, catalog number K182001) or from each 10 cm dish using QuickExtract DNA extraction solution (LGC Lucigen, catalog number QE09050).
[0301] All DNA samples were subjected to subsequent Sanger sequencing analysis and NGS analysis as described in Example 2.
[0302] Example 4. Screening of sgRNA sequences
[0303] Screening of TTR guide RNA in HEK293
[0304] As described in Example 1, sgRNA targeting human TTR was delivered to HEK293. The editing percentage of sgRNA containing each guide sequence was determined, and the guide sequences were then ranked according to the highest editing percentage. The editing data are listed in Tables 5 and Figure 1 middle.
[0305] Table 5: TTR editing data in HEK293 cells using Cas9 protein and sgRNA
[0306]
[0307]
[0308] Screening of TTR guide RNA in HepG2
[0309] As described in Example 1, sgRNA targeting human TTR was delivered to HepG2. The editing percentage of sgRNA containing each guide sequence was determined, and the guide sequences were then ranked according to the highest editing percentage. The editing data are listed in Table 6 below. The data are shown graphically in Figure 2 middle.
[0310] Table 6: TTR editing data using Cas9 protein and sgRNA in HepG2 cells
[0311]
[0312]
[0313] Screening of TTR guide RNAs in primary human hepatocytes As described in Example 1, sgRNAs targeting human TTR were delivered to primary human hepatocytes from different donors using RNAi max. The editing percentage of sgRNAs containing each guide sequence was determined, and the guide sequences were then ranked according to the highest editing percentage. The editing data are listed in Tables 7 and 8 below. The data are shown graphically in Figure 3-4 middle.
[0314] Table 7: TTR editing data in primary human hepatocytes (donor 1) using Cas9 mRNA and sgRNA
[0315] name %edit ART-001-g-int 57 ART-001-g-003 50 ART-001-g-065 38 ART-001-g-064 51 ART-001-g-036 42
[0316] Table 8: TTR editing data in primary human hepatocytes (Donor 2) using Cas9 mRNA and sgRNA
[0317] name %edit ART-001-g-int 57 ART-001-g-013 19 ART-001-g-015 22 ART-001-g-003 30 ART-001-g-065 34 ART-001-g-064 29 ART-001-g-036 30
[0318] Example 5. Dose response of sgRNA in HepG2 and PHH cells
[0319] Lipid nanoparticle formulations of modified sgRNA targeting human TTR sgRNA sequences were tested on HepG2 or primary human hepatocytes at different RNA concentrations. As described in Example 1, HepG2 cells or primary human hepatocytes were inoculated. Both cell lines were cultured at 37°C, 5% CO2 for 24 hours before being treated with LNPs. The LNPs used in the experiments detailed in Tables 20-22 were prepared using the cross-flow procedure described above, but purified using a PD-10 column (GE Healthcare LifeSciences) and concentrated using an Amicon centrifugal filter component (Millipore Sigma), each containing a specified sgRNA and Cas9 mRNA (SEQ ID NO: 1). The LNPs contained ALC-0315, cholesterol, DSPC, and PEG2k-DMG in a molar ratio of 50:38:9:3, respectively, and the N:P ratio was 6.0. The LNPs were cultured at 37°C, 5% CO2 for 5 minutes in a hepatocyte maintenance medium containing 6% serum. After incubation, LNPs were added to HepG2 cells or primary human hepatocytes at 6-12 2-fold concentration increments. Cells were lysed 72 hours after treatment and Sanger sequencing analysis was performed as described in Example 1. The editing percentage of sgRNA containing each guide sequence was determined, and then the guide sequences were ranked according to EC50 value and maximum editing percentage. The dose response curve data of the guide sequences in HepG2 cell line or primary human hepatocytes are shown in Figures 11 to 13The EC50 values and maximum editing percentages are listed below (Tables 9 and 10).
[0320] Table 9 shows the EC50 and maximum editing (expressed as a dose-response curve) of the tested human-specific TTR sgRNA and Spy Cas9 protein on HepG2. The data are graphically displayed in Figure 5 middle.
[0321] Table 9: TTR editing data in HepG2 cells treated with Cas9 protein and sgRNA
[0322] name EC50 Max % Edit ART-001-g-int 0.006 98.22 ART-001-g-001 0.092 88.86 ART-001-g-002 14.220 74.23 ART-001-g-003 4.665 73.79 ART-001-g-065 8.972 86.65 ART-001-g-064 0.0001 94.44 ART-001-g-036 1.395 91.55
[0323] Table 10 shows the EC50 and maximum editing (expressed as a dose response curve) of the tested human-specific TTR sgRNA and Spy Cas9 mRNA formulated in LNP on HepG2. The data are shown graphically in Figure 6 middle.
[0324] Table 10: TTR editing data in HepG2 cells treated with Cas9 mRNA and sgRNA formulated in LNPs
[0325] name EC50 Max % Edit ART-001-g-int 4.2 82.92 ART-001-g-003 13.4 91.67 ART-001-g-065 44.1 68.73 ART-001-g-064 7.5 90.77 ART-001-g-036 14.5 41.37
[0326] Figure 7 Editing in primary human hepatocytes of the tested human-specific TTR sgRNA and Spy Cas9 mRNA formulated in LNPs is shown (represented as concentration response curves).
[0327] Example 4. TTR protein analysis
[0328] Western blot analysis of intracellular TTR
[0329] Primary human hepatocytes from different donors were transfected with sgRNAs containing the guides in Tables 3 and 4 as described in Example 1. The transfected cell pools were cultured for further analysis. Five days after transfection, cells were harvested and whole cell extracts (WCE) were prepared and analyzed by western blot as described in Example 1. The WCE was analyzed by western blot for reduction of TTR protein. The predicted molecular weight of the full-length TTR protein is 16 kD. A band of this molecular weight was observed in the control lane of the western blot.
[0330] The percent reduction of TTR protein was calculated using ePhoto software (Genscript). β-actin was used as a loading control and probed with TTR. The ratio of the densitometry of β-actin to the total area containing the TTR band in each sample was calculated. The percent reduction of TTR protein was determined after normalizing the ratio to the control lane. The results are shown in Figure 8-9 middle.
[0331] ELISA analysis of secreted and intracellular TTR
[0332] Primary human hepatocytes from different donors were transfected with sgRNA containing the guides outlined in Tables 3 and 4 following the protocol outlined in Example 1. Transfected cell pools were cultured for further analysis. Five days after transfection, cell lysates or supernatants were collected and analyzed by ELISA using previously described methods.
[0333] The percent reduction of β-actin was calculated and the percent reduction of TTR protein was determined after normalization to the levels observed in cells transfected with a scrambled sgRNA control. The results are shown in Figure 10-11 middle.
[0334] Example 5. Analysis of large deletion or insertion of sgRNA targeting in PHH
[0335] About 2.8 million human primary hepatocytes were transfected with 4000ng Cas9 mRNA and 800ng sgRNA by RNAiMax. Three days later, genomic DNA was harvested and the sgRNA-targeted sites of about 10kb were amplified by PCR using SuperFi II DNA polymerase (ThermoFisher Sci). Sequencing was performed using the PacBioSEQuel II system using 8MSMRTCell. The percentage of large fragment variations (defined as insertions or deletions greater than 10 base pairs) was determined by dividing the number of large fragment variations by the total number of aligned reads.
[0336] Table 11. There are large structural variations in the targeted regions of different sgRNAs in PHH cells
[0337]
[0338]
[0339] Example 6. Targeted editing efficiency of truncated and / or modified sgRNA in HepG2
[0340] The 20 guide sequences at the 5' end of the sgRNA were further modified by DNA substitution or deletion. 200,000 to 400,000 HepG2 cells were electroporated with 5ug Cas9 protein and 2.5ug sgRNA. Genomic DNA was extracted 2 to 3 days later, and the target region was amplified by PCR and sent for Sanger sequencing. The editing efficiency was determined by ICE analysis.
[0341] Table 12. Targeted editing efficiency of truncated and / or DNA-RNA mixed sgRNAs in HepG2 cells
[0342] sgRNA name Editing efficiency % ART-001-g-int 95 ART-001-g-068 95 ART-001-g-069 95 ART-001-g-070 95 ART-001-g-071 95 ART-001-g-072 95 ART-001-g-073 95 ART-001-g-074 60 ART-001-g-075 59 ART-001-g-076 49 ART-001-g-077 30 ART-001-g-078 16 ART-001-g-079 11 ART-001-g-001 66 ART-001-g-082 59 ART-001-g-083 66 ART-001-g-084 66 ART-001-g-085 66 ART-001-g-086 72 ART-001-g-087 62 ART-001-g-088 21 ART-001-g-089 60
[0343] Example 7. Double-stranded DNA (dsDNA) insertion site of TTR sgRNA in PHH cells
[0344] The potential genomic off-target sites cleaved by Cas9 and corresponding sgRNA were screened using a dsDNA-based assay. 1.4 million PHH cells were transfected with 20 pmol dsDNA, 2000 ng Cas9 protein and 400 ng sgRNA using Lipofectamine RNAiMax. Three days later, genomic DNA was extracted using OceanNano Tech PureBind genomic DNA isolation kit, and NGS assay was performed in NextSeq2000 sequencer (see, e.g., Tsai et al., Nature Biotechnology 33, 187-197; 2015). The dsDNA insertion efficiency of each potential off-target site was calculated as the number of reads at the site divided by the reading at the targeted site (TTR). The sum of the insertion efficiencies of the potential off-target sites ranked 1st and / or top 30 was used as a quantitative reading of the off-target performance of sgRNA.
[0345] Table 13. Potential off-target profiles in PHH cells obtained by dsDNA insertion assay
[0346] sgRNA cell Total number of sites No. 1 / Targeted Top 30 / Targeted ART-001-g-001 Donor 1 132 2.389 7.632 ART-001-g-001 Donor 3 24 0.934 2.764 ART-001-g-003 Donor 1 33 0.040 0.350 ART-001-g-003 Donor 2 2 0.017 0.026 ART-001-g-065 Donor 2 0 0.000 0.000 ART-001-g-065 Donor 1 0 0.000 0.000 ART-001-g-064 Donor 2 1 0.005 0.005 ART-001-g-064 Donor 1 1 0.033 0.033 ART-001-g-064 Donor 3 3 0.016 0.036 ART-001-g-036 Donor 2 0 0.000 0.000 ART-001-g-036 Donor 1 1 0.034 0.034 ART-001-g-int Donor 1 103 0.327 1.531 ART-001-g-int Donor 3 12 0.138 0.556
[0347] Example 8. Off-target analysis of differently modified sgRNAs in HepG2 by dsDNA insertion assay
[0348] A dsDNA insertion-based assay was used to screen for potential genomic off-target sites cleaved by Cas9 and corresponding sgRNA. HepG2 cells were maintained in MEM (Gibco) supplemented with 10% FBS (OPCEL) at 37°C 5% CO2. One million HepG2 cells were electroporated with 200 pmol dsDNA, 35 pmol Cas9 (NEB, EnGen Spy Cas9NLS) protein and 200 pmol sgRNA (general biosystem or genewiz) in a 4D-Nuclefector (LONZA, X-unit). sgRNA contains one or more of the following modifications: deoxyribonucleotide substitution (DNA / RNA mixing), truncation from the 5' end, 2'O fluoride modification. Genomic DNA was extracted and processed for NGS determination in a NextSeq6000 sequencer (see, e.g., Tsai et al., Nature Biotechnology 33, 187-197; 2015). The dsDNA insertion efficiency at each potential off-target site was calculated as the number of reads at that site divided by the number of reads at the targeted site (TTR). The total number of sites found and the highest insertion efficiency of one off-target site were used as semi-quantitative readouts for comparing different sgRNAs.
[0349] Table 14. Potential off-target sites of different sgRNAs in HepG2 cells. This table shows the effects of different sgRNAs.
[0350] sgRNA Total number of sites No. 1 / Targeted Top 30 / Targeted ART-001-g-001 154 0.770 1.580 ART-001-g-002 28 0.121 0.367 ART-001-g-003 14 0.019 0.043 ART-001-g-065 4 0.000 0.001 ART-001-g-064 7 0.199 0.206 ART-001-g-036 13 0.004 0.016 ART-001-g-int 38 0.046 0.107
[0351] Table 15. Potential off-target sites of ART-001-g-001 containing fluorinated nucleotides or deoxyribonucleotides in HepG2 cells
[0352] Table showing the impact of other modifications in ART-001-g-001 on the off-target profile
[0353] sgRNA Other Modifications Total number of sites No. 1 / Targeted Top 30 / Targeted ART-001-g-001 154 0.770 1.580 ART-001-g-093 The 2'OH position of ART-001-g-001 is fluorinated 154 1.092 3.515 ART-001-g-082 Replace U in ART-001-g-001 with a T 74 0.765 1.421 ART-001-g-088 Replace U in ART-001-g-001 with 4 T 40 0.386 0.629 ART-001-g-090 Replace U in ART-001-g-001 with 6 T 18 0.025 0.087
[0354] Table 16. Potential off-target profiles of ART-001-g-002 and ART-001-g003 containing fluorinated nucleotides in HepG2 cells.
[0355] The following table shows the effects of other modifications in ART-001-g-002.
[0356] sgRNA Other Modifications Total number of sites No. 1 / Targeted Top 30 / Targeted ART-001-g-002 28 0.121 0.367 ART-001-g-094 The 2'OH position in ART-001-g-002 is fluorinated 68 0.065 0.155 ART-001-g-003 89 0.017 0.052 ART-001-g-095 The 2'OH site of ART-001-g-003 is fluorinated 154 0.020 0.099
[0357] Table 17. Potential off-target sites of ART-001-g-int containing fluorinated nucleotides or deoxyribonucleotides and / or 5' end truncations in HepG2 cells
[0358] The following table shows the effects of other modifications in ART-001-g-int
[0359] sgRNA Other Modifications Total number of sites No. 1 / Targeted Top 30 / Targeted ART-001-g-int 38 0.046 0.107 ART-001-g-096 Fluoride at the 2'OH site 84 0.441 0.783 ART-001-g-075 Two nucleotides missing at 5' 47 0.078 0.173 ART-001-g-076 Three nucleotides missing at 5' 51 0.047 0.094 ART-001-g-079 Two nucleotides are missing at the 5' position, and 4 Ts replace Us 42 0.015 0.034 ART-001-g-080 Three nucleotides are missing at the 5' position, and four Ts replace Us 80 0.053 0.093 ART-001-g-073 4 Ts instead of U 48 0.007 0.023
[0360] Example 9. Off-target profiles in dsDNA insertion assays of DNA / RNA hybrid sgRNAs in PHH
[0361] In another experiment, 270,000 PHH cells were transfected with 1.5ul Lipofectamine RNAiMax, 500ng Cas9 mRNA, 200ng sgRNA and 300ng dsDNA. Three days later, genomic DNA was extracted with FastPure Cell / Tissue DNA Isolation Micro Kit (Vazyme) and processed for NGS determination in NextSeq6000 sequencer (see, e.g., Tsai et al., Nature Biotechnology 33, 187-197; 2015). The dsDNA insertion efficiency of each potential off-target site was calculated as the number of reads at the site divided by the reads at the targeted site (TTR). The insertion efficiency of the first potential off-target site and / or the sum of the insertion efficiency of the first 30 potential off-target sites was used as a semi-quantitative reading for comparison between different sgRNAs.
[0362] Table 18. Potential off-target profiles of sgRNAs containing deoxyribonucleotides in PHH
[0363]
[0364]
[0365] Example 10. Analysis of large structural variations of TTR sgRNA in HepG2 cells
[0366] HepG2 cells were maintained in MEM (Gibco) supplemented with 10% FBS (OPCEL) at 37°C under 5% CO2. Four million HepG2 cells were electroporated with 1 nmol Cas9 protein and 140 pmol sgRNA in a 4D-Nuclefector (LONZA, X-unit). Three days later, large structural variations were analyzed by NGS methods as described in Yin et al., Cell Discovery 5:18; 2019. Translocation events were quantified as a percentage of total genome editing events.
[0367] Table 19. Large structural variations around the targeted genomic regions in HepG2 cells using Cas9 and different sgRNAs
[0368] sgRNA Translocation ART-001-g-001 0.80% ART-001-g-003 0.02% ART-001-g-065 0.06% ART-001-g-064 0.06% ART-001-g-036 0.03% ART-001-g-int 0.06%
[0369] Example 11. Analysis of large structural variations of TTR sgRNA in the presence or absence of cas9 and fusion exonuclease
[0370] HepG2 cells were electroporated with Cas9 mRNA or Cas9-Trex mRNA (as described in Yin, J., Lu, C. et al., Nat Commun 13, 1204; 2022) and sgRNA. Three days later, genomic DNA was harvested. Large structural variations were analyzed by NGS methods as described in Yin et al., Cell Discovery 5: 18; 2019. Translocation events were quantified as a percentage of total genome editing events.
[0371] Table 20. Large structural variation around targeted genomic regions for cas9 with or without fused exonuclease.
[0372] sgRNA Editor Translocation ART-001-g-001 Cas9 1.72% ART-001-g-001 Cas9Trex 0.28% ART-001-g-003 Cas9 0.01% ART-001-g-003 Cas9Trex 0.01%
[0373] Example 12. Amplicon-based NGS analysis of sgRNA off-targets
[0374] 350,000 PHH cells were transfected with 1.5ul Lipofectamine RNAiMax, 500ng Cas9 or Cas9-TrexmRNA (SEQ ID 355) and 100ng sgRNA. Three days later, genomic DNA was extracted using Zymo genomic DNA purification and concentrator-25. Editing at the targeted site and the first three off-target sites was amplified by PCR using Thermofisher Phusion U Green Multiplex PCR Master Mix. PCR products were purified with KAPA Pure and sequenced on the illuminaNextSeq2000 platform or sent for Sanger sequencing. To account for differences in transfection or editing efficiency between samples, the off-target site editing efficiency was normalized by dividing the targeting efficiency within the same sample.
[0375] Table 21. Off-target reads divided by on-target reads for sgRNAs with different modifications
[0376] The table shows the editing efficiency at three off-target sites divided by the on-target editing efficiency. An empirically determined limit of detection of 0.1% was applied.
[0377]
[0378]
[0379] Example 13. Targeting and off-target efficiency of DNA / RNA hybrid sgRNA delivered using LNP in PHH cells
[0380] 60,000 PHH cells were transfected with LNPs containing Cas9 mRNA and sgRNA. The dose ranged from 0 to 1500 ng total RNA per well. Three days later, genomic DNA was extracted using the FastPure Cell / Tissue DNA Isolation Micro Kit (Vazyme). The targeted site and some off-target sites were amplified by PCR using TaqPro Multiplex DNA Polymerase (Vazyme) and purified using VAHTSDNA purification beads (Vazyme N411-01). NGS sequencing was performed on the Illumina NovaSeq6000 platform.
[0381] Dose-response data are presented graphically in Fig.12 The off-target amp-seq at the maximum dose data is shown in Figure 13-14 middle.
[0382] Example 14. Targeting and off-target analysis of sgRNA modification and Cas9-Trex using lipid transfection
[0383] 270,000 PHH cells were transfected with 1.5ul Lipofectamine RNAiMax, 500ng Cas9 or Cas9-Trex mRNA and 100ng sgRNA in duplicate. Three days later, genomic DNA was extracted using the FastPure Cell / Tissue DNA Isolation Micro Kit (Vazyme). Targeted and off-target sites were amplified by PCR using Taq Pro Multiplex DNA Polymerase (Vazyme) and purified using VAHTS DNA purification beads (Vazyme N411-01). NGS sequencing was performed on the Illumina NovaSeq6000 platform. Fig.15 The targeted gene editing efficiency of the exonuclease fusion and sgRNA modification combinations is graphically displayed. Fig.16 The editing efficiency of the top 4 off-target sites (Table 22) of some sgRNAs with or without exonuclease and / or sgRNA modification is shown graphically. Fig.17 The editing efficiency of the top 5 off-target sites (Table 23) of some sgRNAs with or without exonuclease and / or sgRNA modification is shown graphically.
[0384] Table 22. Off-target site locations
[0385] Off-target sites Chromosome location OT1 chr14:77,332,158-77,332,177 OT2 chr5:91,397,024-91,397,043 OT3 chr6:73,201,227-73,201,246 OT4 chr5:26,758,031-26,758,050
[0386] Table 23. Off-target site locations
[0387] Off-target sites Chromosome location OT2 chr15:66,598,162-66,598,181 OT5 chr21:43,375,900-43,375,919 OT6 chr3:125,963,325-125,963,344 OT7 chr3:123,998,013-123,998,032 OT9 chr4:7,773,740-7,773,759
[0388] Example 15. LNP delivery to mice carrying wild-type (wt) (murine) TTR
[0389] Mice (female mice purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., approximately 6-10 weeks old) were administered an LNP formulation prepared using the lateral flow and TFF procedures described in Example 1, containing sgRNA (ART-001-g-066; SEQ ID NO:277) and Cas9 mRNA in a weight ratio of 1:1. The LNP had an N:P ratio of 3 and contained ALC0315, DSPC, cholesterol, and PEG2k-DMG in a molar ratio of 50:10:38.5:1.5. Animals were treated with a single dose of 3 mg / kg (total RNA content). Blood was collected at 0, 4, 24, 96, 168, and 288 hours after dosing. The group contained 5 mice. Serum TTR was determined using ELISA. The results of serum mouse TTR levels are shown in Fig.18 Serum TTR levels decreased by 99% 168 hours after administration.
[0390] In another set of experiments using wild-type CD-1 mice, LNP formulations prepared using the lateral flow and TFF procedures described above contained sgRNA (ART-001-g-066; SEQ ID NO:277) and Cas9 mRNA in a weight ratio of 1:1. The LNPs contained ALC0315, DSPC, cholesterol, and PEG2k-DMG in molar ratios of 50:10:38.5:1.5, respectively, with an N:P ratio of 3. Dose levels were 3, 1, or 0.3 mg / kg (n=3 / group). Liver editing outcomes were measured using primers designed to amplify regions of interest for Sanger analysis. The results of mouse serum TTR and liver editing are shown in Figure 2. Fig.19 As shown, both serum TTR and liver editing had obvious dose-dependent effects.
[0391] In a separate experiment, LNPs of different sizes as shown in Table 24 were prepared using a lateral flow procedure and concentrated using a centrifugal filter component. The LNPs contained Cas9 mRNA and sgRNA (ART-001-g-066; SEQ ID NO:277) in a weight ratio of 1:1. The LNPs contained ALC0315, DSPC, cholesterol, and PEG2k-DMG in a molar ratio of 50:10:38.5:1.5. Animals were dosed at 1 mg / kg (total RNA content). Blood was collected 7 days after treatment for serum TTR levels and blood chemistry analysis. Serum TTR levels were reduced by more than 95% in all formulations, and LNPs with an average size of 65 nm showed the least risk of liver damage, as shown in Figure 24. Fig. 20A -B.
[0392] Table 24. LNP formulations used for in vivo studies
[0393]
[0394]
[0395] In another study, editing was evaluated using different doses and lipid concentrations in a composition comprising ALC0315. Cas9 mRNA was formulated into LNPs containing a guide RNA targeting TTR (ART-001-g-067; SEQ ID NO:278). These LNPs were formulated in a 1:1 or 1:2 weight ratio of a single sgRNA and Cas9 mRNA. The LNPs were assembled using a lateral flow procedure, and their composition is as described in Table 25. The LNP compositions were analyzed for average particle size, polydispersity (PDI), total RNA content, and RNA encapsulation efficiency as described. The analysis of average particle size, PDI, total RNA content, and RNA encapsulation efficiency is shown in Table 25. CD-1 female mice were dosed intravenously at 0.1, 0.3, and 1 mg / kg. Blood was collected 7 days after treatment for serum TTR analysis. Serum TTR results are shown in Table 25. Fig.21 as shown in .
[0396] Table 25. Composition analysis of LNP formulations
[0397]
[0398] To evaluate the editing efficiency of LNPs containing different amine lipids, LNPs were formulated with a guide RNA targeting TTR (ART-001-g-067; SEQ ID NO: 278) and Cas9 mRNA. LNPs were assembled using a lateral flow procedure with the composition described in Table 26. The average particle size, PDI, and RNA encapsulation efficiency of the LNP compositions were analyzed. CD-1 female mice were dosed intravenously at 0.3 mg / kg. Blood was collected 7 days after treatment for analysis of serum TTR levels. Serum TTR results are shown in Table 26. Fig. 22 shown.
[0399] Table 26. Composition analysis of LNP formulations
[0400] LNP Amine lipids composition EE(%) Z-average size (nm) PDI NTLA-NHP2 LP01 50:9:38:3 85 68 0.04 ART-001-NHP1 ALC0513 50:10:38.5:1.5 92 91 0.07 ART-001-NC Lip. SGM10 50:9.5:37.5:3 96 64 0.05
[0401] Example 16. LNP delivery to humanized TTR mice
[0402] The mice were engineered by knocking in the coding region of the mutant human TTR (V30M) gene at the H11 locus. These humanized mice were administered an LNP formulation containing a guide RNA targeting human TTR. The LNP contained Cas9 mRNA and the corresponding guide RNA in a weight ratio of 2:1. The LNP contained ALC0315, distearoylphosphatidylcholine (DSPC), cholesterol, and PEG2k-DMG in a molar ratio of 50:10:38.5:1.5. The animals were dosed at 1 or 3 mg / kg (total RNA content). Blood was collected at different time points for serum TTR analysis. Serum TTR results are shown in Fig.23 shown.
[0403] In another set of experiments, humanized mice were engineered to delete a region of the endogenous mouse ttr locus and replace it with an orthologous mutant human TTR (V30M) sequence such that the locus encodes human TTR (V30M) protein. LNP formulations containing guide RNA targeting human TTR and Cas9 mRNA in a weight ratio of 1:2 were prepared using the lateral flow and TFF procedures described above. The LNPs contained ALC0315, DSPC, cholesterol, and PEG2k-DMG in molar ratios of 50:10:38.5:1.5, respectively, with an N:P ratio of 3. Dose levels were 1 or 3 mg / kg (n=1 / group). The results of serum human TTR levels are shown in Figure 2. Fig.24 shown.
[0404] Example 17. In vivo editing efficiency of DNA / RNA mixed sgRNA
[0405] In an independent study, humanized mice were genetically modified to replace a region of the native mouse Ttr locus with an orthologous, unmodified human TTR sequence. As a result, the locus was reprogrammed to produce human TTR protein. LNP formulations containing a 1:2 weight ratio of DNA / RNA mixed sgRNA targeting human TTR and Cas9 mRNA were prepared using the lateral flow and TFF procedures described above. The LNPs contained ALC0315, DSPC, cholesterol, and PEG2k-DMG in molar ratios of 50:9.5:37.5:3, respectively, with an N:P ratio of 7. Dosing was performed at 0.1, 0.3, and 0.6 mg / kg (n=1 / group). The results of serum mouse TTR levels and liver editing are shown in Figure 2. Fig.25A -B.
[0406] Other Implementations
[0407] It should be understood that the foregoing description is intended to illustrate and not to limit the scope of the appended claims. Other aspects, advantages and modifications are within the scope of the appended claims.
Claims
1. A guide RNA comprising: a. a sequence selected from SEQ ID NO: 1-47; b. at least 15, 16, 17, 18, 19 or 20 consecutive nucleotides of a sequence selected from SEQ ID NO: 1-47; or c. a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a sequence selected from SEQ ID NOs: 1-47.
2. A guide RNA comprising: a. A sequence selected from SEQ ID NO: 48-81 or SEQ ID NO: 275-307; b. at least 18, 19 or 20 consecutive nucleotides of a sequence selected from SEQ ID NO: 48-81 or SEQ ID NO: 275-307; or c. a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% or 99% identical to a sequence selected from SEQ ID NOs: 48-81 or SEQ ID NOs: 275-307.
3. A vector comprising one or more nucleic acids encoding one or more guide RNAs, wherein the one or more guide RNAs comprise: Ia is selected from one or more sequences of SEQ ID NOs: 1-47; Ib at least 15, 16, 17, 18, 19 or 20 consecutive nucleotides of one or more sequences selected from SEQ ID NOs: 1-47; or Ic one or more sequences that are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a sequence selected from SEQ ID NOs: 1-47; or II.a. one or more sequences selected from SEQ ID NO: 48-81 or SEQ ID NO: 275-307; II.b. at least 18, 19 or 20 consecutive nucleotides of one or more sequences selected from SEQ ID NOs: 48-81 or SEQ ID NOs: 275-307; or II.c. One or more sequences, each of which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a sequence selected from SEQ ID NOs: 48-81 or SEQ ID NOs: 275-307.
4. A composition comprising: (i) a nucleic acid encoding a guide RNA, or a vector comprising a nucleic acid encoding a guide RNA, wherein: The guide RNA comprises: Ia a sequence selected from SEQ ID NOs: 1-47; Ib at least 15, 16, 17, 18, 19 or 20 consecutive nucleotides of a sequence selected from SEQ ID NOs: 1-47; or Ic a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a sequence selected from SEQ ID NOs: 1-47; or II.a. a sequence selected from SEQ ID NOs: 48-81 or SEQ ID NOs: 275-307; II.b. at least 18, 19 or 20 consecutive nucleotides of a sequence selected from SEQ ID NOs: 48-81 or SEQ ID NOs: 275-307; or II.c. a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a sequence selected from SEQ ID NOs: 48-81 or SEQ ID NOs: 275-307. A sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% or 99% identical to a sequence of NO: 275-307; and (ii) an RNA-guided DNA binder, a nucleic acid encoding an RNA-guided DNA binder, or a vector comprising a nucleic acid encoding an RNA-guided DNA binder.
5. The composition of claim 4, wherein the guide RNA is a hybrid DNA-RNA guide.
6. The composition of claim 5, wherein the hybrid DNA-RNA guide comprises a sequence selected from SEQ ID NOs: 302 and 303.
7. The composition of any one of claims 4-6, wherein the RNA-guided DNA binder comprises a Cas nuclease or a Cas nickase.
8. The composition of any one of claims 4-7, wherein the nucleic acid encoding the RNA-guided DNA binder is a Cas9 nucleic acid comprising the amino acid sequence shown in SEQ ID NO: 273 or 274.
9. The composition of any one of claims 4-8, wherein the RNA-guided DNA binder is Cas9 comprising the amino acid sequence shown in SEQ ID NO:
272.
10. The composition of claim 7, wherein the Cas nuclease is a Class 2 Cas nuclease.
11. A composition according to any one of claims 7 or 10, wherein the Cas nuclease is Cas9, Cpf1, C2cl, C2c2 and C2c3 or a modified protein thereof.
12. A composition according to any one of claims 7 or 10-11, wherein the Cas nuclease is a Streptococcus pyogenes or Staphylococcus aureus Cas9 nuclease or a modified protein thereof.
13. A composition according to any one of claims 7 or 10-12, wherein the Cas nuclease is from a type II CRISPR / Cas system.
14. A composition according to any one of claims 4-13, wherein the Cas nuclease is fused to a nuclease exonuclease.
15. The composition of claim 14, wherein the exonuclease is selected from the group consisting of TREX1, TREX2 and MRE11.
16. The composition of any one of claims 14-15, wherein the exonuclease is a truncated exonuclease.
17. A composition according to any one of claims 14-16, wherein the Cas nuclease is fused to the exonuclease at the C-terminus via a GGGGS linker.
18. The composition according to any one of claims 4 to 17, for use in editing the transthyretin (TTR) gene.
19. The composition of claim 18, wherein the editing is calculated as the percentage of the cell population that is edited (percent editing).
20. The composition of claim 19, wherein about 30% to 99% of the cell population is edited.
21. The composition of claim 20, wherein the editing percentage is 30% to 35%, 35% to 40%, 40% to 45%, 45% to 50%, 50% to 55%, 55% to 60%, 60% to 65%, 65% to 70%, 70% to 75%, 75% to 80%, 80% to 85%, 85% to 90%, 90% to 95%, or 95% to 99% of a cell population.
22. The composition of any one of claims 4-21, wherein the composition reduces deposition of amyloid in at least one tissue or organ.
23. The composition of claim 22, wherein the at least one tissue or organ is selected from the group consisting of liver, stomach, colon, sciatic nerve, or dorsal root ganglion.
24. The composition of claim 22, wherein amyloid deposition is measured 8 weeks after administration of the composition.
25. The composition of claim 24, wherein amyloid deposition is compared to a negative control or to levels determined in the subject prior to administration of the composition.
26. The composition of claim 25, wherein amyloid deposition is reduced by at least 20% relative to a corresponding negative control or levels measured in the subject prior to administration of the composition.
27. The composition of claim 24, wherein the composition is administered or delivered at least once.
28. The composition of claim 27, wherein the administration or delivery is performed at the following intervals: (a) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 days; (b) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 weeks; or (c) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 months.
29. The composition of any one of claims 4-28, wherein the guide RNA is at least partially complementary to a target sequence present in a human TTR gene.
30. The composition of claim 29, wherein the target sequence is located in exon 1, 2, 3 or 4 of the human TTR gene.
31. The composition of claim 29, wherein the guide RNA sequence is complementary to a target sequence in the positive strand of a TTR gene.
32. The composition of claim 29, wherein the guide RNA sequence is complementary to a target sequence in the negative strand of TTR.
33. The composition of claim 29, wherein a first guide sequence is complementary to a first target sequence in the positive strand of the TTR gene, and wherein the composition further comprises a second guide sequence that is complementary to a second target sequence in the negative strand of the TTR gene.
34. The composition of any one of claims 4-33, wherein the guide RNA comprises crRNA, and further comprises tracrRNA or a portion thereof, wherein the tracrRNA (trRNA) comprises the nucleotide sequence shown in SEQ ID NO: 257, wherein the trRNA is operably linked to the crRNA.
35. The composition of any one of claims 4-34, wherein the guide RNA is a dual guide RNA (dgRNA).
36. The composition of any one of claims 4-35, wherein the guide RNA is a single guide RNA (sgRNA).
37. The composition of any one of claims 4-36, wherein the guide RNA comprises at least one modification.
38. The composition of claim 37, wherein the at least one modification comprises 2'-O-methyl (2'-O-Me) modified nucleotides, phosphorothioate (PS) bonds between nucleotides, or 2'-fluoro (2'-F) modified nucleotides.
39. The composition of claim 37, wherein the at least one modification comprises a modification at one or more of the first five nucleotides at the 5' end of the guide RNA and / or at one or more of the last five nucleotides at the 3' end of the guide RNA.
40. The composition of claim 37, wherein the at least one modification comprises modification of at least 50% of the nucleotides of the guide RNA.
41. The composition of claim 36, wherein the sgRNA comprises a guide sequence that is at least 90% identical to a sequence selected from SEQ ID NOs: 1-81 or SEQ ID NOs: 275-307.
42. The composition of claim 36, wherein the sgRNA comprises a nucleotide sequence as shown in any one of SEQ ID NOs: 171-251 or SEQ ID NOs: 341-373.
43. The composition of claim 36, wherein the sgRNA comprises a nucleotide sequence that is at least 90% identical to the nucleotide sequence shown in any one of SEQ ID NOs: 171-251 or SEQ ID NOs: 341-373.
44. The composition of any one of claims 41-43, wherein at least a portion of the sgRNA is a hybrid DNA-RNA guide.
45. The composition of claim 44, wherein the sgRNA comprises the nucleotide sequence shown in any one of SEQ ID NOs: 368-369.
46. A composition according to any one of claims 4-45, wherein (i) the nucleic acid encoding the guide RNA or a vector comprising the nucleic acid encoding the guide RNA, and (ii) mRNA encoding the RNA-guided DNA binder, Associated with lipid nanoparticles (LNPs).
47. The composition of claim 46, wherein the LNP comprises ALC0315, DSPC, cholesterol and DMG-PEG2000.
48. The composition of any one of claims 46-47, wherein the LNP has an N / P ratio of about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
49. The composition of claim 48, wherein the N / P ratio is about 3-7.
50. The composition of any one of claims 47-49, wherein ALC0315 accounts for 40 to 60 mol% of the total lipids present in the particle, DSPC accounts for 5 to 15 mol% of the total lipids present in the particle, cholesterol accounts for 30 to 50 mol% of the total lipids present in the particle, and DMG-PEG2000 accounts for 1 to 5 mol% of the total lipids present in the particle.
51. The composition of claim 50, wherein the LNP comprises ALC0315, DSPC, cholesterol, and DMG-PEG2000 in a molar ratio of 50:9.5:37.5:
3.
52. The composition according to any one of claims 4-51, wherein the composition is a pharmaceutical preparation and further comprises a pharmaceutically acceptable carrier.
53. The composition of any one of claims 4-52, wherein the composition reduces or prevents amyloid deposition and / or the formation of amyloid fibrils.
54. The composition of any one of claims 42-54, wherein amyloid deposition and / or amyloid fibril formation is located in the nerves, heart, or gastrointestinal tract.
55. The composition of any one of claims 4-54, wherein administration of the composition results in a deletion or insertion of one or more nucleotides in the TTR gene.
56. The composition of claim 55, wherein the deletion or insertion of one or more nucleotides induces a frameshift or nonsense mutation in the TTR gene.
57. The composition of claim 56, wherein a frameshift or nonsense mutation is induced in the TTR gene of about 20% to about 30% of the cells.
58. The composition of claim 57, wherein the cell is a hepatocyte.
59. The composition of claim 55, wherein the deletion or insertion of one or more nucleotides in the TTR gene is at least 50 times greater than in off-target sites or more.
60. The composition of any one of claims 4-59, wherein administration of the composition reduces the level of monomeric, dimeric and / or tetrameric TTR in the subject.
61. The composition of claim 60, wherein the level of monomeric, dimeric and / or tetrameric TTR is reduced by at least 30%.
62. The composition of claim 60, wherein the level of monomeric, dimeric and / or tetrameric TTR is measured in serum, plasma, blood or cerebrospinal fluid.
63. The composition of any one of claims 4-62, wherein the subject has wild-type ATTR, hereditary ATTR, a family history of ATTR, or familial amyloid polyneuropathy.
64. The composition of claim 63, wherein the subject exhibits neurological symptoms of ATTR.
65. The composition of claim 63, wherein the subject has familial amyloid cardiomyopathy.
66. The composition of claim 63, wherein the subject exhibits cardiac symptoms of ATTR.
67. The composition of any one of claims 4-66, wherein the subject expresses wild-type TTR or TTR with one or more mutations selected from the group consisting of V28S, F33V, F33L, K35N, K35T, A36P, D38V, E42G, G47R, G47V, G47E, T49A, S50R, G53E, E54K, E54G, E54Q, T59K, E61K, Y69H, S77Y, S77F, G83R, A97S, Y114C, V30A, V30G, V30L, V30M, T60A, V122A, V122I, or V122(-).
68. The composition of claim 67, wherein the subject is homozygous for wild-type TTR.
69. The composition of claim 63, wherein following administration, the subject exhibits improvement, stabilization, or reduction in changes in symptoms of sensorimotor neuropathy.
70. The composition of claim 69, wherein improvement, stabilization, or reduction in change in sensory neuropathy is measured using electromyography, nerve conduction studies, or patient reported outcomes.
71. The composition of claim 63, wherein the subject exhibits improvement, stabilization, or slowing of changes in symptoms of congestive heart failure.
72. A composition according to any one of claims 4-71, wherein the composition or pharmaceutical preparation is administered via a viral vector.
73. A composition according to any one of claims 4-71, wherein the composition or pharmaceutical formulation is administered via lipid nanoparticles.
74. A method of modifying a human transthyretin (TTR) gene and / or inducing a double-strand break (DSB) in the TTR gene, comprising administering the composition of any one of claims 4-73 to a cell, wherein the composition recognizes and cleaves a TTR target sequence.
75. A method of reducing TTR serum concentration in a subject, reducing or preventing deposition of amyloid or amyloid fibrils in a subject, and / or treating transthyretin amyloidosis (ATTR) in a subject, comprising administering to a subject in need thereof a composition according to any one of claims 4-73, wherein the composition recognizes and cleaves a TTR target sequence, thereby reducing TTR serum concentration in the subject, reducing or preventing deposition of amyloid or amyloid fibrils in the subject, and / or treating transthyretin amyloidosis (ATTR) in the subject.
76. The method according to any one of claims 74-75, for use in editing the TTR gene.
77. The method of any one of claims 74-76, wherein the RNA-guided DNA binder comprises a Cas nuclease or a Cas nickase.
78. The method of any one of claims 74-77, wherein the nucleic acid encoding the RNA-guided DNA binder is a Cas9 nucleic acid comprising the amino acid sequence shown in SEQ ID NO: 273 or 274.
79. The method of any one of claims 74-78, wherein the RNA-guided DNA binder is Cas9 comprising the amino acid sequence shown in SEQ ID NO:
272.
80. The method of claim 77, wherein the Cas nuclease is a Class 2 Cas nuclease.
81. The method of any one of claims 77 or 80, wherein the Cas nuclease is Cas9, Cpf1, C2cl, C2c2, and C2c3, or a modified protein thereof.
82. The method of claim 77 or 80-81, wherein the Cas nuclease is a Streptococcus pyogenes or Staphylococcus aureus Cas9 nuclease or a modified protein thereof.
83. The method of claims 77 or 80-82, wherein the Cas nuclease is from a type II CRISPR / Cas system.
84. The method of any one of claims 74-83, for use in editing the transthyretin (TTR) gene.
85. The method of claim 84, wherein the editing is calculated as the percentage of the cell population that is edited (percent editing).
86. The method of claim 85, wherein about 30% to 99% of the cell population is edited.
87. The method of claim 86, wherein the percentage of editing is 30% to 35%, 35% to 40%, 40% to 45%, 45% to 50%, 50% to 55%, 55% to 60%, 60% to 65%, 65% to 70%, 70% to 75%, 75% to 80%, 80% to 85%, 85% to 90%, 90% to 95%, or 95% to 99% of a cell population.
88. The method of any one of claims 74-87, wherein the composition reduces deposition of amyloid in at least one tissue or organ.
89. The method of claim 88, wherein the at least one tissue or organ is selected from the group consisting of liver, stomach, colon, sciatic nerve, or dorsal root ganglion.
90. The method of claim 88, wherein amyloid deposition is measured 8 weeks after administration of the composition.
91. The method of claim 90, wherein amyloid deposition is compared to a negative control or levels determined in the subject prior to administration of the composition.
92. The method of claim 91, wherein amyloid deposition is reduced by at least 20% relative to a corresponding negative control or levels measured in the subject prior to administration of the composition.
93. The method of claim 90, wherein the composition is administered or delivered at least once.
94. The method of claim 93, wherein the administering or delivering is performed at the following intervals: (a) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 days; (b) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 weeks; or (c) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 months.
95. The method of any one of claims 74-94, wherein the guide RNA is at least partially complementary to a target sequence present in a human TTR gene.
96. The method of claim 95, wherein the target sequence is located in exon 1, 2, 3 or 4 of the human TTR gene.
97. The method of claim 95, wherein the guide RNA sequence is complementary to a target sequence in the positive strand of a TTR gene.
98. The method of claim 95, wherein the guide RNA sequence is complementary to a target sequence in the negative strand of TTR.
99. The method of claim 95, wherein a first guide sequence is complementary to a first target sequence in the positive strand of the TTR gene, and wherein the composition further comprises a second guide sequence that is complementary to a second target sequence in the negative strand of the TTR gene.
100. The method of any one of claims 74-99, wherein the guide RNA comprises crRNA, and further comprises tracrRNA or a portion thereof, wherein the tracrRNA (trRNA) comprises the nucleotide sequence shown in SEQ ID NO: 257, wherein the trRNA is operably linked to the crRNA.
101. The method of any one of claims 74-99, wherein the guide RNA is a dual guide RNA (dgRNA).
102. The method of any one of claims 74-100, wherein the guide RNA is a single guide (sgRNA).
103. The method of any one of claims 74-102, wherein the guide RNA comprises at least one modification.
104. The method of claim 103, wherein the at least one modification comprises 2'-O-methyl (2'-O-Me) modified nucleotides, phosphorothioate (PS) bonds between nucleotides, or 2'-fluoro (2'-F) modified nucleotides.
105. The method of claim 103, wherein the at least one modification comprises a modification at one or more of the first five nucleotides at the 5' end of the guide RNA and / or at one or more of the last five nucleotides at the 3' end of the guide RNA.
106. The method of claim 103, wherein the at least one modification comprises modification of at least 50% of the nucleotides of the guide RNA.
107. The method of claim 102, wherein the sgRNA comprises a guide sequence that is at least 90% identical to a sequence selected from SEQ ID NOs: 1-81 or SEQ ID NOs: 275-307.
108. The method of claim 102, wherein the sgRNA comprises a hybrid DNA-RNA guide.
109. The method of claim 108, wherein the sgRNA comprises a guide sequence selected from SEQ ID NOs: 302 and 303.
110. The method of claim 102, wherein the sgRNA comprises a nucleotide sequence as shown in any one of SEQ ID NOs: 171-251 or SEQ ID NOs: 341-373.
111. The method of claim 110, wherein at least a portion of the sgRNA is a hybrid DNA-RNA guide.
112. The method of claim 111, wherein the sgRNA comprises the nucleotide sequence shown in any one of SEQ ID NOs: 368-369.
113. The method of claim 102, wherein the sgRNA comprises a nucleotide sequence that is at least 90% identical to the nucleotide sequence shown in any one of SEQ ID NOs: 171-251 or SEQ ID NOs: 341-373.
114. The method of any one of claims 74-113, wherein (i) the nucleic acid encoding the guide RNA or a vector comprising the nucleic acid encoding the guide RNA, and (ii) mRNA encoding the RNA-guided DNA binder, Associated with lipid nanoparticles (LNPs).
115. The method of claim 114, wherein the LNP comprises ALC0315, DSPC, cholesterol, and DMG-PEG2000.
116. The method of any one of claims 114-115, wherein the LNP has an N / P ratio of about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
117. The method of claim 116, wherein the N / P ratio is about 3-7.
118. The method of any one of claims 115-117, wherein ALC0315 accounts for 40 to 60 mol% of the total lipids present in the particles, DSPC accounts for 5 to 15 mol% of the total lipids present in the particles, cholesterol accounts for 30 to 50 mol% of the total lipids present in the particles, and DMG-PEG2000 accounts for 1 to 5 mol% of the total lipids present in the particles.
119. The method of claim 118, wherein the LNP comprises ALC0315, DSPC, cholesterol, and DMG-PEG2000 in a molar ratio of 50:9.5:37.5:
3.
120. The method of any one of claims 74-119, wherein the composition is a pharmaceutical formulation and further comprises a pharmaceutically acceptable carrier.
121. The method of any one of claims 74-120, wherein the composition reduces or prevents amyloid deposition and / or the formation of amyloid fibrils.
122. The method of claim 121, wherein amyloid deposition and / or amyloid fibril formation is located in the nerves, heart, or gastrointestinal tract.
123. The method of any one of claims 74-122, wherein administration of the composition results in a deletion or insertion of one or more nucleotides in the TTR gene.
124. The method of claim 123, wherein the deletion or insertion of one or more nucleotides induces a frameshift or nonsense mutation in the TTR gene.
125. The method of claim 124, wherein a frameshift or nonsense mutation is induced in the TTR gene of about 20% to about 30% of the cells.
126. The method of claim 125, wherein the cell is a hepatocyte.
127. The method of claim 123, wherein the deletion or insertion of one or more nucleotides in the TTR gene is at least 50 times greater than in off-target sites or more.
128. The method of any one of claims 74-127, wherein administration of the composition reduces the level of monomer, dimer and / or tetramer TTR in the subject.
129. The method of claim 128, wherein the level of monomeric, dimeric and / or tetrameric TTR is reduced by at least 30%.
130. The method of claim 128, wherein the level of monomeric, dimeric and / or tetrameric TTR is measured in serum, plasma, blood or cerebrospinal fluid.
131. The method of any one of claims 74-130, wherein the subject has wild-type ATTR, hereditary ATTR, a family history of ATTR, or familial amyloid polyneuropathy.
132. The method of claim 131, wherein the subject exhibits neurological symptoms of ATTR.
133. The method of claim 131, wherein the subject has familial amyloid cardiomyopathy.
134. The method of claim 131, wherein the subject exhibits cardiac symptoms of ATTR.
135. The method of any one of claims 74-134, wherein the subject expresses wild-type TTR or TTR with one or more mutations selected from the group consisting of V28S, F33V, F33L, K35N, K35T, A36P, D38V, E42G, G47R, G47V, G47E, T49A, S50R, G53E, E54K, E54G, E54Q, T59K, E61K, Y69H, S77Y, S77F, G83R, A97S, Y114C, V30A, V30G, V30L, V30M, T60A, V122A, V122I, or V122(-).
136. The method of claim 135, wherein the subject is homozygous for wild-type TTR.
137. The method of claim 132, wherein following administration, the subject exhibits improvement, stabilization, or slowing of changes in symptoms of sensorimotor neuropathy.
138. The method of claim 137, wherein improvement, stabilization, or reduction in changes in sensory neuropathy is measured using electromyography, nerve conduction studies, or patient-reported outcomes.
139. The method of claim 133, wherein the subject exhibits improvement, stabilization, or slowing of changes in symptoms of congestive heart failure.
140. The method of any one of claims 74-139, wherein the composition or pharmaceutical formulation is administered via a viral vector or via lipid nanoparticles.
141. Use of a composition according to any one of claims 4-73 in the preparation of a medicament for treating a human subject suffering from transthyretin amyloidosis (ATTR).
142. A composition comprising: (i) a hybrid DNA-RNA guide comprising a sequence selected from SEQ ID NO: 302 or 303; (ii) Cas nuclease fused to exonuclease; wherein the hybrid DNA-RNA guide and the Cas nuclease fused to the exonuclease are associated with LNPs, wherein the LNPs comprise ALC0315, DSPC, cholesterol, and DMG-PEG2000 in a molar ratio of 50:9.5:37.5:
3.
143. A method of modifying a human transthyretin (TTR) gene and / or inducing a double-strand break (DSB) in a TTR gene, comprising administering a composition according to claim 142 to a human subject in need thereof.
Citation Information
Cited By
Compositions comprising a TTR guide RNA and a polynucleotide encoding an RNA-guided DNA binding agent and methods using the same
WO2026149586A1
